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Die Idiopathische Pulmonale Fibrose (IPF) ist eine progredient verlaufende 
Lungenparenchymerkrankung unbekannter Ursache. Sie geht mit einer deutlich reduzierten 
Lebenserwartung einher. Die bisher einzigen pharmakologischen Therapieoptionen sind 
Nintedanib und Pirfenidon, welche den Krankheitsverlauf verlangsamen, jedoch nicht aufhalten. 
Die Voraussetzung für die Entwicklung neuer therapeutischer Optionen ist ein tieferes 
Verständnis des antifibrotischen Wirkprinzips beider Medikamente. Insbesondere deren Effekt 
auf Alveolarepithel Typ (AT) II Zellen, welche eine Schlüsselrolle in der Pathogenese von IPF 
einnehmen, wurde bisher kaum untersucht. Das Ziel der hier vorgestellten Studie war es daher, 
den Effekt von Nintedanib und Pirfenidon auf AT II Zellen in ex-vivo Lungenschnitten sowie in der 
primären murinen AT II Zellkultur zu untersuchen. Als Lungenfibrose-Modelle wurden im 
Wesentlichen das Bleomycin-Mausmodell sowie der Fibrotische Cocktail (FC), bestehend aus 
verschiedenen Wachstumsfaktoren, in humanen ex-vivo Lungenschnitten verwendet.   
Zunächst konnten wir zeigen, dass fibrotische murine sowie humane Lungenschnitte ex-vivo 
entscheidende Charakteristika der pulmonalen Fibrose über den Kulturzeitraum aufwiesen. Wir 
konnten weiterhin zeigen, dass Nintedanib und Pirfenidon die Gen- und Proteinexpression 
fibrotischer Marker in murinen ex-vivo Lungenschnitten sowie in primärer muriner AT II Zellkultur 
inhibierten. Nintedanib, nicht jedoch Pirfenidon, stimulierte die Expression von AT II Zellmarkern, 
insbesondere die des Oberflächenmarkers Surfactant-Protein C (SP-C), sowohl in AT II Zellkultur 
als auch in murinen und humanen ex-vivo Lungenschnitten. Es zeigte sich, dass Nkx2.1 und Hopx, 
beide essenzielle Transkriptionsfaktoren der AT II-Transdifferenzierung, durch Nintedanib 
hochreguliert wurden. Interessanterweise konnte der Effekt von Nintedanib auf AT II 
Zellmarkerexpression, nicht aber auf fibrotische Markerexpression in humanen ex-vivo 
Lungenschnitten, rekapituliert werden.   
Zusammenfassend zeigt unsere Studie die Anwendbarkeit von ex-vivo Lungenschnitten zur 
präklinischen Testung antifibrotischer Wirkstoffe am Beispiel von Nintedanib und Pirfenidon. Des 
Weiteren beobachteten wir unterschiedliche Effekte von Nintedanib und Pirfenidon auf AT II 
Zellen, die potentiell zur antifibrotischen Wirkung von diesen beitragen.   
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2. SUMMARY 
Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease of unknown cause with 
restricted therapeutic options. To date, the only approved drugs known to slow disease 
progression are Nintedanib and Pirfenidone. However, the life expectancy is still limited with or 
without treatment. Therefore, novel therapeutic options are needed. In this context, a more in-
depth understanding of the mechanism of action of Nintedanib and Pirfenidone might help to 
identify novel therapeutic targets. Furthermore, the potential effect of these drugs on alveolar 
epithelial cells with being the key driver of the disease can be of particular interest. Therefore, in 
this study we aim to delineate the potential anti-fibrotic effects of both Nintedanib and 
Pirfenidone on alveolar epithelial Type II (AT II) cells using primary murine AT II cell culture as 
well as ex-vivo 3D-Lung Tissue Cultures (3D-LTCs). The Bleomycin-induced lung fibrosis model in 
mice and the Fibrotic Cocktail (FC), consisting of multiple pro-fibrotic growth factors, in human 
3D-LTCs were mainly utilized for this study. 
Firstly, we demonstrated profibrotic hallmarks to be recapitulated in both murine and human 
fibrotic ex-vivo 3D-LTCs during culture duration. Nintedanib and Pirfenidone subsequently 
inhibited fibrotic marker gene and protein expression in murine ex-vivo 3D-LTCs and primary 
murine AT II cell culture. We showed Nintedanib, but not Pirfenidone, to induce AT II cell marker 
expression, in particular Surfactant Protein-C (SP-C), in both primary murine AT II cell culture and 
ex-vivo 3D-LTCs. Our data further indicated that this effect is partly mediated by Nkx2.1 and Hopx, 
two transcription factors being crucial for AT II transdifferentiation, both being upregulated upon 
Nintedanib treatment. Interestingly, we were able to recapitulate the effect of Nintedanib on AT 
II cell marker, but not on fibrotic marker expression in human ex-vivo 3D-LTCs.  
In summary, we show murine and human ex-vivo 3D-LTCs to be a feasible tool for preclinical drug 
testing. We further showed differential effects of Nintedanib and Pirfenidone on epithelial cell 




3. INTRODUCTION  
 
3.1 Interstitial lung diseases    
Interstitial lung diseases (ILD), also referred to as diffuse parenchymal lung diseases (DPLDs), 
comprise a heterogeneous group of parenchymal lung diseases of known causes, such as drug 
toxicity, occupational exposures or connective tissue diseases, and unknown causes. The latter 
are called idiopathic interstitial pneumonias (IIP) and are subdivided into idiopathic pulmonary 
fibrosis (IPF) and “other IIPs”. The distinction is made upon the presence/absence of a usual 
interstitial pneumonia (UIP) pattern. Thus, IPF, is defined as chronic progressive interstitial lung 
disease of unknown cause, restricted to the lung and associated with the presence of a radiologic 
or histopathologic UIP pattern (Raghu et al. 2011, 2002)  
 
3.2 Epidemiology 
Affected patients are typically elderly men (median age of patients is 65 years) with a smoking 
history (King, Pardo and Selman 2011, Collard 2010a, Raghu et al. 2011). Known risk factors for 
developing IPF are cigarette smoking, virus infections, gastroesophageal reflux and 
environmental exposures such as wood and stone dust. The estimated prevalence of IPF ranges 
between 10-60 per 100 000 people and incidence 2-3 per 100 000 people which significantly 
increases with age. In total 3 million patients are affected globally by the disease. The life 
expectancy of 3-5 years at time of the diagnosis if not treated is comparable to the one of cancer 
patients or worse (Martinez et al. 2017). 
 
3.3 Clinical presentation and diagnosis 
IPF diagnosis must be considered in all elderly exhibiting unexplained progressive dyspnea and 
dry cough. Finger clubbing and bilateral inspiratory crackles in the basal areas can be found in 
the physical examination. In end stages of the disease peripheral edema and right heart failure 
might be evident. To establish the diagnosis of IPF the following criteria must be met: This include 
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1) the exclusion of other ILDs causes by a detailed medical history and examination, 2) 
identification of usual interstitial pneumonia (UIP) pattern, including  honeycombing, reticular 
opacities and traction bronchiectasis, using high resolution computed tomography (HRCT)  or 3) 
combination of surgical biopsy and HRCT pattern, if the HRCT features alone are inconclusive 
(Raghu et al. 2011). Due to the risk of major complications and mortality surgical biopsy must 
only be performed if histopathological findings possibly alter outcome prediction and/or 
treatment decisions (Martinez et al. 2017). The definite diagnosis is made in a multidisciplinary 
approach including clinicians and radiologists based on the 2011 American Thoracic Society, 
European Respiratory Society, Japanese Respiratory and Latin American Thoracic Association 
consensus statement (Raghu et al. 2011). 
 





Figure 1: UIP pattern in HRCT. (A-D) Transverse and coronal high-resolution computed tomography (HRCT) 
depicting usual interstitial pneumonia (UIP) pattern, such as honeycombing and ground-glass opacification. The 
UIP pattern predominantly manifests in subpleural/basal areas. (E) Magnification of the honeycomb cysts. The 
characteristic cluster formed are pointed out by arrows. (Figure modified from Raghu et al. 2018) 
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3.4 Histopathological features 
The histopathological hallmarks of IPF are referred to as usual interstitial pneumonia (UIP) 
pattern. This UIP pattern is characterized by a patchy distributed interstitial fibrosis with 
subsequent architectural distortion and honeycombing, a cystic airspace filled with mucus and 
lined with bronchiolar epithelium (Richeldi, Collard and Jones 2017). Fibroblast foci, defined as 
aggregates of activated (myo-)fibroblasts with adjacent hyperplastic alveolar epithelium, are 
located at the interface of fibrotic and normal lung parenchyma. They presumably represent 
areas of active fibrogenesis (Jones et al. 2016, Yanagi et al. 2015). Inflammation, that was 
historically thought be the cause of IPF, is only mild with lymphocytes and plasma cell infiltrations 
(Raghu et al. 2011). Notably, mortality was shown to correlate with the number of fibrotic foci in 
IPF patients, but not with inflammatory activity (King et al. 2001, Harada et al. 2013, Jones et al. 
2016, Selman, King and Pardo 2001).  
 
3.5 Pathophysiological features  
Historically, IPF was thought to result from chronic inflammation with subsequent fibrosis 
formation and architectural distortion. However, both the absence of active inflammation in 
histopathology and the ineffectiveness of anti-inflammatory therapeutics led to re-consideration 
of the prevailing hypothesis (Selman and Pardo 2002, Selman et al. 2001). In the present 
paradigm, IPF is believed to result from an exaggerated repair process in response to impaired 
alveolar epithelium leading to a dysregulated epithelial-mesenchymal-crosstalk, subsequent 
fibroblast activation and proliferation and excessive extracellular matrix deposition (King et al. 
2011, Richeldi et al. 2017). In more detail, alveolar type (AT) II cell impairment is caused by both 
genetic predisposition, aging processes and repetitive injury due to occupational exposure to 
toxins (Selman and Pardo 2012, Boucher 2011). As a result, AT II cells, that are crucial for 
maintenance of lung homeostasis secreting surfactant protein C (SP-C) to reduce surface tension 
and serve as precursors of AT I cells, 1) become either hyperplastic or elongated large cells,  which 
then 2) synthesize  various pro-fibrotic growth factors and cytokines, such as Transforming growth 
factor-β (TGF-β) and matrix-metalloproteinases (MMPs) and 3) lose their regenerative capacity 
by becoming increasingly apoptotic or senescent (Selman and Pardo 2002).  These aberrantly 
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activated epithelial cells secreting a plethora of growth factors subsequently cause to the 
expansion of the (myo-)fibroblasts population by inducing the proliferation of resident fibroblasts 
(Warshamana, Corti and Brody 2001), attracting circulating fibrocytes (Andersson-Sjoland et al. 
2008) and epithelial-to mesenchymal-transition (EMT) (DeMaio et al. 2012). In-vivo studies 
demonstrated EMT to constitute to a small portion of (myo-)fibroblasts in fibrosis, however it 
remains unclear if these cells substantially contribute to ECM formation in fibrosis (Fernandez 
and Eickelberg 2012b, Wolters, Collard and Jones 2014, Rock et al. 2011). Thus, the aberrant 
functioning of epithelial cells results in (myo-)fibroblast activation and proliferation, excessive 
ECM deposition and subsequent fibroblast foci formation. An aberrant epithelial-mesenchymal 
crosstalk starts with not only alveolar epithelial cells but (myo-)fibroblasts driving disease 
progression by inducing epithelial cell apoptosis (Selman and Pardo 2014, Hagimoto et al. 2002, 
Waghray et al. 2005). These (myo-)fibroblasts undergo phenotypic and functional changes 
exhibiting an invasive and proliferative phenotype including the resistance to apoptosis (Li et al. 
2011, Ramos et al. 2001, Wolters et al. 2014).  Moreover, not only (myo-)fibroblasts but the 
deposited ECM is profoundly altered in IPF (Parker et al. 2014, Zhou et al. 2013). For instance, 
the ECM stiffening in IPF alters (myo-)fibroblast behavior by inducing fibroblast to myofibroblast 
transdifferentiation and increasing ECM gene expression. A positive feedback loop is formed with 
altered ECM regulating miRNA expression in adjacent cells, thus inducing matrix gene expression 
(Parker et al. 2014). 
The recovery of the alveolar epithelial barrier is crucial for maintenance of lung homeostasis; 
however, repetitive impairment of the alveolar epithelium leads to an aberrant repair response 
eventually resulting in fibrosis. During the normal wound healing process alveolar epithelial cell 
migrate towards the denuded area. Upon a provisional matrix, mainly consisting of fibronectin, 
AT II cells proliferate and transdifferentiate to AT I, thus closing the wounded area (Yanagi et al. 
2015). Activated (myo-)fibroblasts simultaneously proliferate and migrate to the site of injury 
rebuilding the ECM scaffold (Kendall and Feghali-Bostwick 2014). This process is accompanied by 
close epithelial-mesenchymal-crosstalk with AT II secreting a plethora of chemokines and growth 
factors and transient reactivation of developmental pathways. In fibrosis impaired epithelial cell 
integrity due to genetic predisposition and aging processes (e.g. cellular senescence, telomere 
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attrition) causes the alveolar epithelial cells to respond improperly to repetitive injury upon 
occupational exposures (Figure 2).  An excessive wound healing response is initiated and 
perpetuates as the disease progresses. 







Figure 2: An integral model of genetic and environmental factors contributing to alveolar epithelial cell 
disintegrity in the aged lung. (Figure modified from Selman et al. 2014) 
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3.5.1 Deregulated pathways 
A large number of aberrantly activated signaling pathways, including TGF-β, connective tissue 
growth factor (CTGF), platelet-derived growth factor (PDGF), tumor necrosis factor α and 
wingless/in1 (WNT)- signaling, contribute to IPF pathogenesis (Martinez et al. 2017, Selman, 
Pardo and Kaminski 2008). TGF-β, in particular, is a main driver of fibrosis development and 
progression exhibiting pleiotropic pro-fibrotic properties (Fernandez and Eickelberg 2012a). TGF-
β superfamily is involved in embryonic lung morphogenesis, maintaining organ homeostasis and 
tissue repair in the adult (Shi and Massague 2003). Although all TGF-β (β1, β2, β3) isoforms are 
known to be involved in IPF pathogenesis, TGF-β1 plays a predominant role (Fernandez and 
Eickelberg 2012a). Activation of latent TGF-β1 is facilitated via αvβ6 integrin which is increasingly 
expressed on alveolar epithelial cells in IPF (Munger et al. 1999). TGF-β1 overexpression in 
alveolar type II (AT II) cells subsequently resulted in AT II hyperplasia along with fibroblast 
proliferation, myofibroblast formation and enhanced ECM deposition (Xu et al. 2003).  Moreover, 
TGF- β1 was shown to induce epithelial to mesenchymal transition (EMT) and apoptosis in 
alveolar epithelial cells in the disease (Siegel and Massague 2003, Xu, Lamouille and Derynck 
2009, Ding et al. 2017). Targeting TGF-β signaling substantially reduced the fibrotic burden in 
experimental fibrosis mouse models; however, these findings have not been successfully 
translated into the clinics yet. Because TGF-β signaling is important for maintaining physiological 
functions, its inhibition might be detrimental to organ homeostasis (Varga and Pasche 2008). 
More recently, a clinical phase II trial showed αvβ6 inhibition to substantially reduce active TGF-
β signaling with good tolerability in IPF (Mouded et al.). Further results must be awaited. 
Developmental pathways, such as WNT, Sonic Hedgehog and Notch signaling, are known to be 
reactivated in IPF (Martinez et al. 2017, Baarsma and Konigshoff 2017, Selman et al. 2008). Thus, 
WNT family member expression along with β-catenin nuclear translocation, a sign for activated 
WNT-signaling, was shown to be increased in lung tissue of IPF patients (Konigshoff et al. 2008).  
Moreover, WNT-target gene expression, especially WNT1-inducible signaling protein-1 (Wisp1) 
expression was enhanced in IPF lung tissue suggesting increased functional WNT-signaling in the 
diseased lung (Konigshoff et al. 2009, Baarsma and Konigshoff 2017). The subsequent inhibition 
of WISP1 resulted in attenuated Bleomycin induced lung fibrosis proving genes regulated by WNT 
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signaling to be promising therapeutic targets (Konigshoff et al. 2009). It was shown that AT II to 
AT I transdifferentiation is regulated by WNT/β-catenin signaling suggesting that WNT-signaling 
which might be beneficial in the initial repair response following injury (Flozak et al. 2010). 
However, with disease progression the persistent activation of WNT-signaling results in aberrant 
alveolar epithelial cell functioning (Baarsma and Konigshoff 2017). Thus, it was shown that the 
induction of WNT/β-catenin signaling in the alveolar epithelium (in-vitro) leads to both 
phenotypic and functional changes, such as EMT and secretion of pro- inflammatory and pro-
fibrotic cytokine secretion, respectively (Aumiller et al. 2013, Ulsamer et al. 2012). Similar to 
WNT-/β-catenin signaling, both Sonic Hedge Hog (SHH) ligands and receptors (e.g. PTCH1), 
regulating mesenchymal proliferation and branching morphogenesis during lung development 
(Kugler et al. 2015), was upregulated in IPF lung tissue but not in healthy controls (Coon et al. 
2006, Stewart et al. 2003). Interestingly, inhibition of SHH failed to prevent the development of 
fibrosis in the Bleomycin mouse model (Moshai et al. 2014) whereas overexpression worsened 
experimental lung fibrosis (Liu et al. 2013). In-vitro studies showed prolonged survival and 
increased proliferation of fibroblasts after SHH induction suggesting that SHH signaling is crucial 
for fibrosis perpetuation (Liu et al. 2013, Kugler et al. 2015).  
Many developmental pathways that are essential in organ development and silenced later on, 
are aberrantly reactivated in idiopathic pulmonary fibrosis (Selman et al. 2008). They have been 
linked to both pathogenesis and progression of the disease and subsequent inhibition led to the 
attenuation of experimental fibrosis making them to promising targets for future therapies in IPF. 
 
3.5.2 Aging 
There is a clear link, both biological and epidemiological, between IPF and aging (Collard 2010b, 
Thannickal 2013). Aging is indeed accompanied with the loss of cell integrity and function 
resulting in an increased vulnerability to disease development. However, not only the natural 
aging process but its acceleration due to repetitive injury and repair plays a critical role in the 
induction and perpetuation of IPF. Thus, the major hallmarks of aging have been shown to 
contribute to IPF pathogenesis (Lopez-Otin et al. 2013). Alveolar epithelial impairment in the 
 10 
disease specifically is linked to age-related changes, such as telomere attrition, increased cellular 
senescence and mitochondrial dysfunction (Selman and Pardo 2014, Collard 2010b). Recurring 
damage to the alveolar epithelial barrier with subsequent division of adjacent cells is known to 
lead to progenitor cell exhaustion and cellular dysfunction making proper wound healing 
impossible (Chilosi et al. 2013). For instance, abnormally abbreviated telomeres are not only 
documented in the epithelium of IPF patients (Alder et al. 2008), but the length is associated with 
a worse survival in IPF patients (Stuart et al. 2014). Moreover, genetic mutations in familiar IPF 
are related to telomere biology highlighting the impact of aging-related changes in the 
pathogenesis of the disease (Armanios et al. 2007). Similarly, cellular senescence is increased in 
the alveolar epithelium of IPF patients contributing to disease pathogenesis by secreting a 
plethora of soluble molecules and thus, affecting the adjactend cellular microenviroment 
(Minagawa et al. 2011, Disayabutr et al. 2016). This “Senescence-Associated Secretory 
Phenotype” (SASP) consists of pro-inflammaory cytokines (e.g. IL-6) and metalloproteinases, such 
as MMP7, known to be upregulated in IPF (Coppé et al. 2010, Takizawa et al. 1997, Rosas et al. 
2008). Moreover, depletion of senscence cells restored epithelial cell function in in-vitro and in 
ex-vivo 3D-Lung Tissue Cultures (3D-LTCs) representing a novel therapeutic option in the 
treatment of age-related diseases (Lehmann et al. 2017). However, the role of cellular 
senescence in fibrosis remains controversial exhibiting both anti- and pro-fibrotic effects 
(Minagawa et al. 2011, Cui et al. 2017).  
Furthermore, not only IPF but other chronic lung diseases, such as chronic obstructive pulmonary 
disease (COPD) exhibit certain hallmarks of aging (e.g. telomere attrition, cellular senescence and 
mitochondrial dysfunction) raising the question what makes patients specifically prone to IPF.  In 
this context, it has been proposed that genetic predisposition along with distinct gene expression 
patterns and epigenetic reprogramming could potentially be decisive (Selman and Pardo 2014).  
 
3.5.3 Genetics 
Genetic susceptibility is known to substantially contribute to disease development both in 
familial and sporadic IPF. Known genetic mutations in familiar IPF, which can be held accountable 
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for 20% of overall IPF cases, are related to telomere maintenance (TERT, TERC, RTEL, PARN) and 
surfactant malfunction (SFTPC, SFTPA2) highlighting the impact of both impaired epithelial cell 
integrity and aging processes in disease pathogenesis (Richeldi et al. 2017). A genome wide 
linkage screen revealed a MUC5B promotor polymorphism (rs35705950) to be the most 
abundant genetic mutation in both sporadic and familial IPF with 38% and 34%, respectively 
(Spagnolo and Cottin 2017, Yang et al. 2015). MUC5B is expressed in the bronchiolar epithelium 
maintaining mucociliary clearance as part of immune defense indicating the potential impact of 
altered distal airways epithelium in disease pathogenesis. Intriguingly, carrier of the MUC5B 
variant showed improved overall survival suggesting that increased mucin production due the 
MUC5B polymorphism is linked to improved host defense (Peljto et al. 2013, Yang et al. 2015). 
As the MUC5B promotor variant is the most common genetic risk factor for the development of 
IPF in the general population, it was further proposed as biomarker for early fibrosis detection 
(Yang et al. 2015). However, the MUC5B promotor polymorphism is present in 19 % of the 
population whereas IPF is found in less than 1% indicating that other genetic mutations and 
environmental toxins contribute to the development of IPF (Yang et al. 2015).  Therefore, other 
genetic risk factors for sporadic IPF have been identified, including genes associated with DNA 
repair (TERT, TERC) and cell-cell-contact (DSP and DPP9) (Yang et al. 2015).  Interestingly, Toll 
interacting protein (TOLLIP) variants, regulating TGF-β signaling as well as Toll-like receptor 
mediated immune response, were associated with reduced susceptibility for IPF. However, 
patients who developed IPF despite carrying the TOLLIP polymorphism exhibited increased 
mortality (Noth et al. 2013).  
Genetic factors combined with environmental exposure substantially contribute to IPF 
development in patients.  This can have potential implications both for the understanding of the 
disease pathogenesis and detection/treatment of IPF (Spagnolo and Cottin 2017): 1) Surfactant 
protein and telomerase-associated gene mutations in familiar IPF are both related to alveolar 
epithelial cell maintenance, thus emphasizing the importance of impaired of epithelial cell 
integrity at the onset of the disease, 2) testing for the abundantly expressed MUC5B promotor 
variant combined with HRCT gives the unique opportunity to detect subclinical IPF stages and 
thus improving the patients prognosis by early treatment, 3) testing for genetic mutations might 
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help to predict the course of the disease as the MUC5B promotor mutation is associated with 
better prognosis whereas patients with the TOLLIP variant have higher mortality and 4) genetic 
mutations potentially change the response to anti-fibrotic treatment.  
 
3.5.4 Epigenetic reprogramming 
Common risk factors for the development of IPF, such as aging, male gender, cigarette smoking 
and genetic alteration, are also potent inducer of epigenetic reprogramming (Helling and Yang 
2015). These epigenetic changes, such as DNA methylation, histone alterations and microRNA 
deregulation alter the individual’s gene expression profile, thus translating environmental 
influences into genetic regulation (Yang and Schwartz 2015). Yang et al. demonstrated 2 130 gene 
regions to be differentially methylated in IPF patients compared to control, from which 738 
exhibited significant gene expression changes. Approximately 10-15% of the detected 
differentially methylated genes were associated with IPF pathogenesis, highlighting the impact 
of DNA methylation on gene regulation in IPF (Yang et al. 2014). Similarly, microRNAs (miRNA), 
regulating protein translation by targeting mRNA, are differentially expressed in IPF tissue 
compared to control (Pandit et al. 2010). By interacting with pro-fibrotic signaling pathways, such 
as TGF-β, these miRNAs exhibit both pro- and anti-fibrotic effects. For instance, miRNA-21 is 
highly increased in IPF tissue and Bleomycin mouse fibrosis promoting TGF-β signaling by 
targeting SMAD7. The subsequent miRNA- 21 neutralization resulted in attenuated Bleomycin 
induced lung fibrosis in mice (Liu et al. 2010). On the contrary, miRNA led-7d was shown to be 
significantly decreased by TGF-β in IPF (Pandit et al. 2010).  Studies investigating structural 
chromatin changes in IPF showed that, for instance, deficient acetylation of histone with 
consecutive hypermethylation led to repression of anti-fibrotic genes, such as cyclooxygenase-2, 
thus contributing to disease progression (Coward et al. 2010). In line with this, histone 
deacetylases (HDACs) were found to be highly upregulated in IPF tissue (Korfei et al. 2015). 
Epigenetic profiling facilitates a better understanding of IPF pathogenesis and further helps to 
develop innovative therapeutic and diagnostic approaches (Yang et al. 2014). DNA methylation 
targeting drugs as well as histone deacetylase inhibitors are already utilized in the treatment of 
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IPF patients are treated according to the American Thoracic Society, European Respiratory 
Society, Japanese Respiratory and Latin American Thoracic Association consensus statement 
updated in 2015. In the course of recent clinical trials many emerging therapies have been 
identified as either harmful or ineffective (Richeldi et al. 2017). Therefore, strong 
recommendations were made against the combination of prednisone, azathioprine and N-
acetylcysteine, a recent worldwide standard in the treatment of fibrosis, due to the PANTHER 
study showing an increased mortality and hospitalization rate (Izumi, Iikura and Hirano 2012). 
Similar to the immunosuppressive therapy the usage of Ambrisentan, a selective endothelin 
receptor antagonist, and anticoagulation with warfarin lack any favorable effect more likely 
accelerating disease progression (Raghu et al. 2013, Noth et al. 2012).  N-acetyl-cysteine 
monotherapy might have beneficial effects in patients with a certain TOLLIP polymorphism 
(Oldham et al. 2015); however, conditional recommendations were made against its use 
(Martinez et al. 2017). Thus, Nintedanib and Pirfenidone, remain to be the only approved drugs 
for the treatment of IPF known to be effective. The underlying mechanisms of action remain 
poorly understood, though. 
 
3.6.1 Pirfenidone 
Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridon) is a synthetic pyridine derivative that has been 
approved for treatment of mild-to moderate IPF in 2011 by the European Medicines Agency 
(EMA) and 2014 by the Food and Drug Administration (FDA) (Richeldi et al. 2017).  Originally 
being developed as an analgesic and anti-pyretic agent in 1974, its anti-fibrotic properties were 
first described in 1994 in an animal fibrosis model by Margolin et al. (Gan, Herzog and Gomer 
2011, George and Wells 2017). The first phase III trial by Taniguchi et al. in 2010 reported a 
significant reduction in vital capacity decline which is known to correlate with survival (Taniguchi 
 14 
et al. 2010)  whereas following CAPACITY trials showed differential results one supporting the 
initial findings while the other one being not significant (Noble et al. 2011). Due to the 
discordance the ASCEND phase III trial was performed showing reduced disease progression and 
increased progression-free survival in the Pirfenidone group compared to placebo (King et al. 
2014, Richeldi et al. 2017). More recently, Pirfenidone was shown to have potential pro-survival 
effects (Nathan et al. 2017). Reported adverse events were gastrointestinal symptoms such as 
dyspepsia and vomiting, photosensitivity, skin rash and elevated liver enzymes leading to 
discontinuation of treatment in one fifth (20%) of the patients (Richeldi et al. 2017).        
 
   
 
 
3.6.1.1 Pharmacokinetics   
Pirfenidone is an orally available small molecule. With absorption it is rapidly degraded mainly 
by cytochrome CYP1A2 into three metabolites, 5-carboxypirfenidone, 5-hydroxypirfenidone and 
4- hydroxypirfenidone and subsequently eliminated via urine (Togami, Kanehira and Tada 2015). 
These metabolites were shown to partially exhibit anti-fibrotic effects. Pirfenidone concentration 
reaches its maximum at (Tmax) 0.5 hours and is eliminated within 3 hours (Rubino et al. 2009, Shi 
et al. 2007, Schaefer et al. 2011). Togami et al. demonstrated the tissue distribution to be 
relatively low in the lung compared to kidneys and liver. This can potentially be held accountable 
Figure 3: FVC outcomes from all Pirfenidone phase-III trails. A treatment benefit in reduced FCV decline was 
observed at each timepoint. (Figure modified from Noble et al. 2016) 
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for the need of high dosing (2403mg/day) in clinical therapy and subsequent side effects (Togami 
et al. 2015).                                                                                                 
 
3.6.1.2 Mode of action 
Pirfenidone was shown to combine anti-inflammatory, anti-oxidant and anti-fibrotic properties 
in both animal and in-vitro fibrosis models of the lung, liver, kidney and heart (Schaefer et al. 
2011, Carter 2011). However, the precise mode of action remains unknown.  
                                                                                                         
Anti-fibrotic action  
The anti-fibrotic action of Pirfenidone can be mainly attributed to the downregulation of pro-
fibrotic growth factors TGF-β, PDGF-A/-B and bFGF expression, thus inhibiting (myo-)fibroblast 
activation and proliferation, collagen synthesis and deposition of extracellular matrix (Oku et al. 
2008, Iyer, Gurujeyalakshmi and Giri 1999b). In-vitro studies demonstrated Pirfenidone to 
significantly inhibit TGF-β mediated cellular events, including fibroblast to myofibroblast 
differentiation and proliferation, ECM production and EMT. Pirfenidone was shown to inhibit key 
regulating factors of the TGF-β signaling pathway, such as phosphorylation of SMAD3, p38 and 
Akt (Conte et al. 2014). Similar effects were observed in a human retinal pigment epithelial (RPE) 
cell line with Pirfenidone impeding the accumulation of Smad2/3 in the nucleus (Choi et al. 2012). 
In-vivo, it has been demonstrated that Pirfenidone sufficiently inhibits TGF-β and SMAD mRNA 
expression levels (Iyer et al. 1999b). These studies suggest that Pirfenidone directly modulate 
TGF-β signaling by blocking its downstream targets.  However, it has been recently proposed that 
Pirfenidone also regulates TGF-β via suppression of GLI transcription factors (Didiasova et al. 
2017). Furthermore, Pirfenidone was shown to substantially downregulate PDGF and FGF levels 
in a Bleomycin hamster model (Gurujeyalakshmi, Hollinger and Giri 1999). Moreover, PDGF-
induced hepatic stellate cell proliferation and collagen secretion was reduced by Pirfenidone 
treatment.  However, direct PDGF pathway regulation by Pirfenidone via receptor auto-
phosphorylation, ERK 1/2 or pp70 activation was not shown (Di Sario et al. 2002). 
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Major ECM component collagen I, in particular, plays a central role in fibrogenesis (Decaris et al. 
2014). Several studies demonstrated that Pirfenidone affects collagen (I) expression, secretion 
and fibril formation in both human fibroblasts and epithelial cells (Nakayama et al. 2008, Hisatomi 
et al. 2012, Knuppel et al. 2017, Shin et al. 2015). Collagen specific chaperone Heat shock protein 
(HSP) 47 was shown to be decreased by Pirfenidone upon TGF-β treatment (Nakayama et al. 
2008). Animal studies supported the in-vitro findings with Pirfenidone decreasing hydroxyproline 
secretion (Oku et al. 2008). Moreover, Pirfenidone significantly downregulated MMP 2 and TIMP-
1 levels in a liver fibrosis model (Di Sario, 2004). 
 
Anti-inflammatory action 
Pirfenidone exerts its anti-inflammatory properties via suppressing pro-inflammatory cytokine 
levels including IL-6, IL-8, IL-12, TNF-α and IL-1β, increasing anti-inflammatory agents (e.g. IL-10) 
and reducing inflammatory cell recruitment and proliferation (Oku et al. 2002, Nakazato et al. 
2002, Oku et al. 2008).  However, the exact mode of action remains elusive. For instance, in-vivo 
studies demonstrated Pirfenidone to inhibit TNF-α production at a translational level while IL-10 
expression was enhanced at a transcriptional level (Nakazato et al. 2002). Moreover, Pirfenidone 
was shown to reduce macrophage (M1, M2) and neutrophil infiltration by inhibiting chemotactic 
cytokines, such as MCP-1 and CINC (Tsuchiya et al. 2004, Chen et al. 2013). Additionally, 
Pirfenidone inhibited TCR-induced CD4+ lymphocyte proliferation in-vitro and in-vivo (Visner et 
al. 2009). Pro-inflammatory cytokines and chemokines released by both macrophages and 
lymphocytes were subsequently diminished by Pirfenidone (Visner et al. 2009, Chen et al. 2013). 
 
Anti-oxidant action 
Increased oxidative stress has been previously implicated in the IPF pathogenesis. The imbalance 
towards the enhanced production of reactive oxidant species (ROS) was shown to result in 
cellular dysfunction and consecutive tissue damage leading to fibrosis formation (Kliment and 
Oury 2010). Pirfenidone was demonstrated to exert anti-oxidant properties in both in-vitro and 
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in-vivo fibrosis models (Giri et al. 1999, Iyer, Gurujeyalakshmi and Giri 1999a). Pirfenidone both 
acts as anti-oxidant scavenger neutralizing ROS by complex formation (Mitani et al. 2008, Misra 
and Rabideau 2000) and induces cellular antioxidant glutathione synthesis (Macias-Barragan et 
al. 2014). Moreover, it was shown that Pirfenidone regulates Nrf2/Bach1 balance, two key 
regulators of (anti-)oxidant gene expression, resulting in the increased Nrf2 dependent 
production of anti-oxidants in-vitro and in-vivo (Liu et al. 2017). 
 
3.6.2 Nintedanib 
Nintedanib (formerly known as BIBF 1120) is a tyrosine kinase receptor inhibitor that was initially 
designed as an antianginal agent for cancer treatment (Wollin et al. 2015a). Tyrosine kinase 
receptors, including VEGFR, PDGFR and FGFR have been implicated in IPF pathogenesis being key 
regulators of fibroblast proliferation, migration and myofibroblast transformation (Wollin et al. 
2014). Nintedanib was approved in 2014 by the FDA followed by EMA in 2015 for the treatment 
of IPF patients based on the findings of TOMORROW phase II trial and INPULSIS-1 and -2, two 
phase III trials. Both phase II and III trials demonstrated Nintedanib to reduce the annual FVC 
decline by approximately 50% compared to placebo and the number of acute exacerbations, thus 
decelerating disease progression in IPF patients (Richeldi et al. 2011, Richeldi et al. 2014). Long- 
term treatment with Nintedanib showed a reduced all-cause mortality compared to placebo and 
deceleration of disease progression beyond 52 weeks (Richeldi et al. 2018). The most reported 
side effect was diarrhea leading to termination of treatment in 5% of the patients (Richeldi et al. 
2014). 
With IPF and other ILDs sharing clinical and pathophysiological hallmarks, the potential benefit 
of Nintedanib and Pirfenidone, in the treatment of non-IPF ILD has recently gained attention 
(Collins and Raghu 2019). In-vitro and in-vivo preclinical studies demonstrated Nintedanib to 
exert anti-fibrotic effects in non-IPF ILDs (Wollin et al. 2019a).  Moreover, the INBUILD study 
showed Nintedanib to reduce the annual decline of the FVC rate compared to placebo making 






3.6.2.1 Pharmacokinetics  
After oral administration small-molecule Nintedanib is promptly absorbed reaching its maximum 
concentration within 2-4 h [0,14 (ng/mL)/mg]. The half-life is 10-15 hours. Due to high first-pass-
metabolism, the bioavailability is only around 5%. Nintedanib showed high plasma albumin 
binding with approximately 98% in humans. Nintedanib is predominantly degraded by hydrolytic 
ester cleavage into BIBF 1202 with following glucuronidation and elimination via bile. A small 
fraction is demethylated by CYP3A4 into BIBF 1053. However, CYP dependent metabolism and 
interaction with CYP modulating drugs of Nintedanib is negligible (Roth et al. 2015, Wind et al. 
2019).  
Figure 4: Long-term results of the TOMORROW study. (A) Annual FVC decline (B, C) Kaplan-Meier survival curves 
for (B) time until first acute exacerbation and (C) time until death. Patients of the TOMORROW study (phase 1 
and 2) and its open-label extension were included. The comparator group was treated with placebo in phase 1 
and a daily dose of 50mg of Nintedanib in phase 2. They were able to increase to 150mg twice daily of Nintedanib 
in the open-label extension. The Nintedanib group was treated with 150mg twice daily of Nintedanib. (Figure 
modified from Richeldi et al. 2018) 
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3.6.2.2 Mode of action 
Nintedanib binds competitively to the ATP-binding pocket of following intracellular kinase 
receptor kinase domains: VEGFR 1–3, PDGFR-α and -β and FGFR 1–3, thereby blocking 
autophosphorylation and downstream signaling cascade of these receptors (Wind et al. 2019). 
Additionally, Nintedanib was shown to directly target non-receptor kinases Src, Lyn, Lck, Flt-3 and 
RET (Roth et al. 2009, Hilberg et al. 2008a). It can be assumed that Nintedanib exerts its anti-
fibrotic action via binding to these tyrosine kinase receptors. Hostettler et al. showed PDGF, FGF 
and VEGF induced fibrotic changes are significantly inhibited by Nintedanib (Hostettler et al. 
2014). However, the impact of yet partly known targets on the mode of action still remains to be 
further elucidated. 
              
Anti-fibrotic action  
Targets of Nintedanib therapy, PDGF(R), FGF(R) and VEGF(R), are potent fibroblast mitogens 
inducing excessive proliferation, migration and myofibroblast transdifferentiation of fibroblasts 
in the context of disease. Nintedanib was shown to block PDGF, FGF and VEGF induced fibroblast 
proliferation and motility as well as collagen secretion in IPF and control fibroblasts. Sato et al. 
also demonstrated Nintedanib to directly interfere with fibrocyte function, mesenchymal 
progenitor cells, which have been proposed to be major source for fibroblasts in IPF (Sato et al. 
2017, Andersson-Sjoland et al. 2008). Moreover, Nintedanib increased matrix metalloproteinase 
(MMP)-2 levels while reducing its counterpart tissue inhibitor of metalloproteinase (TIMP)-2, 
contributing to enhanced degradation of ECM (Hostettler et al. 2014, Wollin et al. 2014). It was 
further shown that Nintedanib directly interferes with TGF-β signaling, thus inhibiting TGF- β 
dependent fibroblast to myofibroblast transdifferentiation, ECM protein expression and collagen 
fibril formation (Hostettler et al. 2014, Rangarajan et al. 2016). However, whether this effect is 
conveyed by Nintedanib binding directly to TGF-β receptor (TGFRβII) and/or nonreceptor SRC 
kinases remained inconclusive (Rangarajan et al. 2016).  Furthermore, Nintedanib was 
demonstrated to reduce the fibrotic burden following bleomycin induced lung fibrosis in mice 
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assessed by histologic analysis as well as TGF-β mRNA levels and pro-collagen I (Wollin et al. 
2014).   
 
Anti-inflammatory action  
Anti-inflammatory activity of Nintedanib was demonstrated in animal models of pulmonary 
fibrosis by attenuation of inflammatory cell counts and pro-inflammatory cytokines in 
bronchoalveolar lavage fluids (BALF) (Wollin et al. 2014).  It can be assumed that these anti-
inflammatory effects are partly conveyed by Nintedanib blocking non-receptor kinase Lck 
dependent T-cell proliferation and pro-inflammatory chemokine production (Hilberg et al. 2008a, 
Wollin et al. 2019b). It was further shown that Nintedanib blocks M2 macrophage polarization, a 
pro-fibrotic phenotype releasing CCL18, thereby promoting fibroblasts depositing collagen 
(Zhang et al. 2018, Wollin et al. 2019b). 
 
Anti-angiogenic action  
The potential impact of dysregulated angiogenesis on IPF pathogenesis remains controversial 
(Renzoni 2004).  However, antianginal agent Nintedanib was shown to restore microvascular 
architecture by reducing vessel density in mice exposed to Bleomycin (Ackermann et al. 2017). In 
vitro, Nintedanib attenuated proliferation of pericytes, endothelial cells and smooth muscles cells 
which have been shown to be crucial for lung angiogenesis (Hilberg et al. 2008b, Wollin et al. 






3.7 Aims of the study 
It is well accepted that repetitive epithelial injury and the consecutive secretion of pro-fibrotic 
mediators by aberrant epithelium contribute to the development of IPF. Therefore, targeting the 
abnormal alveolar epithelium in fibrosis can be of particular interest. To date, the only 
therapeutic options known to be effective in decelerating disease progression are Nintedanib 
and Pirfenidone. However, if these drugs potentially affect epithelial functioning remains elusive. 
Therefore, in this study we aim to investigate this question as follows:  
“Do Nintedanib and Pirfenidone affect alveolar epithelial cell behavior and function in a favorable 
way?”  
To do so, we used ex-vivo 3D- Lung Tissue Cultures (3D-LTCs) generated from mice and human 
tissue to resemble the in-vivo situation as close as possible. For a more in depth understanding 
we additionally used murine primary alveolar type II (pmAT II) cell monoculture. Both murine 3D-
LTCs and pmAT II cells were either derived from Bleomycin-treated mice or treated with TGF-β 
as fibrotic stimulus in-vitro. We further validated our findings using the human 3D-LTCs subjected 
to TGF-β or a novel fibrotic cocktail to mimic an “early fibrosis like” stage which was established 
in our lab.  
Additional questions were addressed as follows:  
1) Are both murine and human 3D-LTCs an adequate tool for testing the anti-fibrotic action 
of these drugs? 
2) Which concentrations are effective for ex-vivo treatment without compromising cell 
viability? Do they correspond with concentrations found in patients? 
3) Thus, can Nintedanib and Pirfenidone sufficiently inhibit mesenchymal gene expression 




4. MATERIALS AND METHODS 
4.1 Materials 
 
4.1.1 Laboratory Equipment  
Table 1: Laboratory Equipment 
Product  Company 
+4° Fridge, Medline  
-20° Freezer, Medline  
-80° Freezer, U570 Premium  
Autoclave DX -45  
Autoclave VX -120  
Balance XS4002S 
Centrifuge Mikro 200R  
Centrifuge Rotina 420R 
Cell incubator BBD6620 
Liebherr; Biberach, Germany 
Liebherr; Biberach, Germany 
New Brunswick; Hamburg, Germany 
Systec; Wettenberg, Germany  
Systec; Wettenberg, Germany  
Mettler Toledo, Greifensee, Germany 
Hettich Zentrifugen; Tuttlingen, Germany 
Hettich Zentrifugen; Tuttlingen, Germany 
Thermo Fisher Scientific; Darmstadt, Germany 
Gel imaging system ChemiDoc XRS+ Biorad; Hercules, CA, USA 
Herasafe KS180, Cell Culture bench Pierce, Thermo Fisher Scientific; Schwerte, Germany 
Light Cycler LC480 II                                              Roche Diagnostics; Mannheim, Germany 
Mastercycler Nexus Eppendorf; Hamburg, Germany 
Micro-Dismembrator S Thermo Fisher Scientific; Darmstadt, Germany 
Microscope LSM 710 (confocal) Zeiss; Jena, Germany 
Microsprayer Aerosolizer 
MilliQ Advantage A10 
Mini Microcentrifuge 230 V 
Penn-Century, Wyndmoor, PA, USA 
Merck Millipore; Darmstadt, Germany 
Corning LSE, Kaiserslautern, Germany 
Mini-PROTEAN Tetra Cell 
Mulitpipette Stream  
Biorad, USA 
Eppendorf; Hamburg, Germany 
Nano Drop ND-1000 PeqLab; Erlangen, Germany 
SunriseTM (ELISA-Reader) Tecan; Crailsheim, Germany 
Syringe pump "Aladdin" AL-1000 
Thermomixer Compact 
World Precision instruments; Sarasosta, FL, USA 
Eppendorf; Hamburg, Germany 
Tissue Lyser II 
 
Quiagen; Hilden, Germany 
 23 
4.1.2 Software 
Table 2: Software 
Software Company 
Endnote X7.0.2 Thomson Reuters; San Francisco, CA, USA 
GraphPad Prism 5.00  GraphPad Software; La Jolla, CA, USA 
Image Lab Version 5.0 Biorad; Hercules, CA, USA 
IMARIS x 64 Bitplane,, Zurich, Switzerland 
LightCycler® 480 SW 1.5 Roche Diagnostics; Mannheim, Germany 
Magelan Software Tecan; Crailsheim, Germany 
Zen 2010 Zeiss; Jena, Germany 
 
4.1.3 Chemicals and reagents 
Table 3: Chemicals and reagents 
Product  Company 
Acetone AppliChem; Darmstadt, Germany 
Agarose, low melting point Sigma-Aldrich; Taufkirchen, Germany 
Amphotericin B solution (250µg/ml) Sigma-Aldrich; Taufkirchen, Germany 
Biopsy punsh (4mm, 6mm diameter) pfm medical; Köln, Germany 
Bleomycin sulfate Almirall; Barcelona, Spain 
Bovine serum albumin (BSA) Sigma-Aldrich; Taufkirchen, Germany 
Cell Proliferation Reagent WST-1 Roche Diagnostics; Mannheim, Germany 
Complete® Mini without EDTA  Roche Diagnostics; Mannheim, Germany 
DAPI Sigma-Aldrich; Taufkirchen, Germany 
Desoxyribonucleotides mix (dNTPs) Thermo Fisher Scientific; Heidelberg, Germany  
Dimethyl sulfoxide (DMSO) Carl Roth; Karlsruhe, Germany 
Dithiothreitol (DTT) AppliChem; Darmstadt, Germany 
D-MEM/F12 Gibco, Life Technologies; Carlsbad, CA, USA 
DNase/RNAse-free water Gibco, Life Technologies; Carlsbad, CA, USA 
Ethanol (p.a.) AppliChem; Darmstadt, Germany 
Fetal bovine serum (FBS) PAA/GE Healthcare; Fairfield, CT, USA 
Fluorescence mounting medium  Dako; Hamburg, Germany 
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Glucose AppliChem; Darmstadt, Germany 
HEPES Life Technologies; Carlsbad, CA, USA 
Ketamine Bela-pharm; Vechta, Germany 
Lysophosphatidic acid (LPA) Cayman Chemical; Ann Arbor, MI, USA 
Methanol  AppliChem; Darmstadt, Germany 
MuLV Reverse Transcriptase 5,000 U Applied Biosystems, Invitrogen, Life Technologies; 
Carlsbad, USA 
Nintedanib  Selleck; Houston, TX, USA 
Non-fat dried milk powder AppliChem; Darmstadt, Germany 
Plateled derived growth factor- AB (PDGF-AB) Gibco, Life Technologies; Carlsbad, CA, USA 
Penicillin-Streptomycin  Gibco, Life Technologies; Carlsbad, CA, USA 
Phosphate burrerd saline Gibco, Life Technologies; Carlsbad, CA, USA 
PhosSTOP Phosphatase Inhibitor  Roche Diagnostics; Mannheim, Germany 
Pirfenidone Selleck; Houston, TX, USA 
Proteinase K Pierce, Thermo Fisher Scientific; Schwerte, Germany 
Protein marker V Peqlab; Erlngen, Germany 
Random hexamers Applied Biosystems, Life Technologies; Carlsbad, CA, 
USA 
Rekombinant TGF-β1 protein R&D Systems; Minneapolis, USA 
Restore Plus Western Blot Stripping Buffer Pierce, Thermo Fisher Scientific; Schwerte, Germany 
RNase inhibitor 20 U/µl Applied Biosystems, Invitrogen, Life Technologies; 
Carlsbad, USA 
Rotiphorese Gel 30 (37,5:1) 500 ml Carl Roth; Karlsruhe, Germany 
Sodium dodecyl sulphate (SDS) pellets Carl Roth; Karlsruhe, Germany 
Sodium chloride AppliChem; Darmstadt, Germany 
SuperSignal West Dura Extended Duration 
Substrate 
Pierce, Thermo Fisher Scientific; Schwerte, Germany 
SuperSignal West Femto Substrate Pierce, Thermo Fisher Scientific; Schwerte, Germany 
SybrSafe (10,000x in DMSO) Invitrogen Life Technologies; Carlsbad, CA, USA 
TEMED AppliChem; Darmstadt, Germany 
Tumor necrosis factor-α R&D Systems; Minneapolis, USA 
T-PER Tissue Protein Extraction Reagent Pierce, Thermo Fisher Scientific; Schwerte, Germany 
Tris base, buffer grade AppliChem; Darmstadt, Germany 
Triton X-100 AppliChem; Darmstadt, Germany 
Tween 20 AppliChem; Darmstadt, Germany 
UltraPure DNase/RNase-Free Distilled Water Invitrogen Life Technologies; Carlsbad, CA, USA 
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WST-1 Roche Diagnostics; Mannheim, Germany 
Xylazinhydrochloride cp-pharma; Burgdorf, Germany 
 
 
4.1.4 Consumables  
Table 4: Consumables 
Product  Company 
Cell culture flask Thermo Fisher Scientific; Darmstadt, Germany 
Cell culture well (6-well, 12-well, 96-well) TPP; Trasadingen, Switzerland 
Cryotubes Thermo Fisher Scientific; Darmstadt, Germany 
Falcon tubes (15ml, 50ml) BD Bioscience, Heidelberg, Germany 
Filter tips Biozym Scientific;Hessisch Oldendorf, Germany 
Grinding steel balls Neolab; Heidelberg, Germany 
Multipipette tips Eppendorf; Hamburg, Germany 
Nitrocellulose membrane Sigma-Aldrich; Taufkirchen, Germany 
Nylon Meshes (pore size 100µm, 20µm, 10µm) Sefar; Heiden, Germany 
Scalpel B.Braun; Melsungen, Germany 
Syringes B.Braun; Melsungen, Germany 
Parafilm Sealing Film Bemis Packaging; Neenah, WI, USA 
PCR plates and sealing foil Kisker Biotech;Steinfurt, Germany 
PVDF membranes Sigma-Aldrich; Taufkirchen, Germany 
Reaction tubes  Greiner Bio-One; Frickenhausen, Germany 







4.1.5 Buffers, solutions and media  
Table 5: Buffers, solutions and media 
Buffer/solutions Compounds Concentration 




















































































   




Table 6: Kits 
Product  Company 
BCA Protein Assay Kit Pierce, Thermo Fisher Scientific; Schwerte, Germany 
IL-6 ELISA R&D, Minneapolis, Minnesota, USA 
Peqlab Total RNA Kit  Peqlab, Erlangen, Germany 
PerfectPure RNA Fibrous Tissue Kit 5Prime; Hilden, Germany 
RNeasy Mini Kit Qiagen; Hilden, Germany 
SFTPC ELISA Cusabio; Wuhan, China 
WISP1 ELISA R&D, Minneapolis, Minnesota, USA 
 
4.1.7 Antibodies 
Table 7: Primary Antibodies for immunofluorescence 
antibody origin company, catalog number dilution 
alpha-SMA mouse Sigma-Aldrich; Taufkirchen, Germany; A5228 1:500 
Collagen 1 rabbit Rockland; Gilbertsville, PA, USA; 600-401-103 1:100 
E-Cadherin mouse BD Biosciences; Heidelberg; Germany; 610181 1:200 
Fibronectin rabbit Santa Cruz Biotechnology, TX, USA; sc-9068  1:100 
Podoplanin goat R&D; Minneapolis, MN, USA; AF3244 1:100 
SFTPC, pro- rabbit Millipore; Billerica, MA, USA; AB3786 1:500 
Tenc mouse Abcam; Cambridge, UK; ab58954-100 1:100 
 
Table 8: Primary Antibodies for Western Blot 
antibody origin company, catalog number dilution 
β-actin mouse Sigma-Aldrich; Taufkirchen, Germany; A3854 1:50,000 
Collagen 1 rabbit Rockland; Gilbertsville, PA, USA; 600-401-103 1:1000 
E-Cadherin mouse BD Biosciences; Heidelberg; Germany; 610181 1:1000 
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antibody origin company, catalog number dilution 
SFTPC, pro- rabbit Abcam; Cambridge, UK; ab40879 1:1000 
 
Table 9: Secondary Antibodies for immunofluorescence  
antibody origin company, catalog number dilution 
Goat-IgG (H+L), Alexa Fluor 488 
conjugated 
donkey Invitrogen Life Technologies; Carlsbad, CA, 
USA; A-11055 
1:1,000 
Mouse-IgG (H+L), Alexa Fluor 
555 conjugated 
rabbit Invitrogen Life Technologies; Carlsbad, CA, 
USA; A-21424 
1:1,000 
Rabbit-IgG (H-L), Alexa Fluor 555 
conjugated 




Table 10: Secondary Antibody for Western Blot, HRP linked 
antibody origin company, catalog number dilution 
Mouse IgG sheep GE Healthcare; Freiburg, Germany 1:4,000 
Rabbit IgG donkey GE Healthcare; Freiburg, Germany 1:10,000 
 
Table 11: Antibodies used for FACS analysis (primary and secondary) 
antibody origin company, catalog number dilution 
SFTPC, pro- rabbit Millipore, ab3786 1:2000 
Rabbit-IgG (H-L), 
Alexa Fluor 488 
conjugated 








Table 12: Murine quantitative PCR primers  
Gene Sequence 5’ - 3’  
Acta2 fw GCTGGTGATGATGCTCCCA rv GCCCATTCCAACCATTACTCC 
Col1a1 fw CCAAGAAGACATCCCTGAAGTCA   rv TGCACGTCATCGCACACA 
Fn1 fw GGTGTAGCACAACTTCCAATTACG rv GGAATTTCCGCCTCGAGTCT 
Hopx fw TCTCCATCCTTAGTCAGACGC rv TCTCCATCCTTAGTCAGACGC 
HPRT fw CCTAAGATGAGCGCAAGTTGAA rv CCACAGGACTAGAACACCTGCTAA 
Nkx2.1 fw AGGACACCATGCGGAACAG   rv CCATGCCGCTCATATTCATGC 
Sftpc fw AGCAAAGAGGTCCTGATGGA rv GAGCAGAGCCCCTACAATCA 
T1α fw ACAG GTGCTACTGGAGGGCTT rv TCCTCTAAGGGAGGCTTCGTC 
 
Table 13: Human quantitative PCR Primers 










NKX2.1 fw AGCACACGACTCCGTTCTC rv GCCCACTTTCTTGTAGCTTTCC 
SFTPC fw GCCCAGTGCACCTGAAACGC rv GCCCAGTGCACCTGAAACGC 







4.2.1 Human tissue 
Macroscopically tumor-free lung tissue obtained from patients undergoing lung cancer resection 
surgeries was used for the generation of 3D-LTCs.  The absence of IPF/ILD was verified by 
pathology and CT. Human tissue samples subsequently subjected to the fibrotic cocktail were 
attained from two patients (one male 62 years, one female, 80 years) with squamous cell 
carcinoma and one patient being diagnosed with a carcinoid lung tumor (male, 48 years). The 
smoking history of these patients was not known. Human 3D-LTCs were generated and cultured 
as previously described (Uhl et al. 2015). Human tissue samples were provided by the Asklepios 
Biobank of Lung Diseases and the CPC BioArchive CPC-M at the University Hospital Grosshadern 
of the Ludwig Maximilian University (LMU). All experiments using human tissue were approved 
by the local ethic committee of the LMU (project number: 333-10,455-12). Written informed 
consent by all participants of this study was obtained.  
 
4.2.2 Animal experiments 
Six to eight-month-old female pathogen-free C57BL/6 mice obtained from Charles River were 
used throughout all studies. All experiments were conducted according to the ethics committee 
of the Helmholtz Zentrum Munich (Germany) guidelines and approved by the regional council of 
Upper Bavaria (Germany). The mice had free access to water and food and were housed in 
facilities with constant temperature, humidity and 12h light cycles. To induce experimental lung 
fibrosis, Bleomycin was applied intratracheally as a single dose (2U/kg/body weight) using the 
Micro-Sprayer Aerosolizer. Control mice received PBS only. At day 14 post-installation, the mice 




4.2.3 Primary murine alveolar type II cell isolation and culture                                                                                                                  
Primary murine alveolar type II cells (pmAT II) were isolated from mice as previously described 
(Mutze et al. 2015, Demaio et al. 2009). In brief, after flushing the pulmonary circulation system 
with sterile PBS, the lung was inflated with dispase followed by low gelling agarose. The lungs 
were subsequently incubated for 45 minutes at room temperature. After digestion the tissue was 
minced and filtered through 100µm, 20µm and 10µm nylon meshes. After centrifugation the 
pellets were re-suspended and fibroblast negative selection was done by adherence using cell 
culture dishes. Lymphocytes, macrophages and endothelial cells were removed from the cell 
suspension with CD45 and CD31 conjugated magnetic beads, respectively. Cell purity was 
checked routinely by cell morphology and immunofluorescence analysis. After plating the pmAT 
II were cultured in DMEM-F12 complemented with 10% FCS, 2mM 1-glutamine, 1% 
penicillin/streptomycin, 3,6 mg/ml glucose and 10M HEPES for 24h to promote attachment. 
Before stimulation, cells were synchronized by culturing them for 12h hours in 0.1% FCS 
starvation medium with identical composition as medium for cell attachment. Fibrotic pmAT II 
cell were then treated with Nintedanib (0,1µM) or Pirfenidone (100µM) and respective DMSO 
control. pmAT II derived from wild-type mice were pre-treated with Nintedanib ((0,1µM, 1µM) 
or Pirfenidone (100µM, 500µM) and respective DMSO control for 1 hour and subsequently 











Figure 5: Primary murine alveolar epithelial type II cell isolation. The pmATII cells were obtained either from 
wild-type or Bleomycin/PBS-treated mice. Mice lungs were filled with agarose, minced and filtered through 
meshes. The pmATII cells were separated from other cell types using Magnetic Cell Isolation.  
AT II cells are obtained 
using Magnetic cell 
Isolation 
Dispase low melting agarose Mince tissue 
Uncoated dishes 
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4.2.4 Murine ex-vivo 3D-Lung tissue culture  
Murine 3D-LTCs were generated as described afore (Uhl et al. 2015). Briefly, the anaesthetized 
mice were intubated using an endotracheal tube and the chest cavity was opened after dissecting 
the diaphragm. After flushing the pulmonary circulation system through the heart with sterile 
PBS, the lungs were inflated via an endotracheal tube with warm low gelling agarose dissolved in 
cultivation medium (2% by weight in DMEM-F12) using a syringe pump. After harvesting the lung, 
the lobes were separated and cut into 300µm thick slices using the vibratome at a speed of 10-
12 µm/s, an amplitude of 1mm and frequency of 100Hz. The 3D-LTCs were cultured in DMEM-
F12 supplemented with 0.1% FCS and antibiotics (1% penicillin/streptomycin and amphotericin 
B). 3D-LTCS obtained from healthy mice were pre-treated with Pirfenidone (100µM, 500µM, 
2.5mM) or Nintedanib (0.1µM, 1µM, 10µM) and the respective DMSO control. After one hour 
TGF- β (2ng/ml) was added. 3D-LTCs obtained from PBS- or Bleomycin-treated mice at day 14 
post-installation were stimulated either with Pirfenidone (100µM, 500µM, 2.5mM) or Nintedanib 
(0.1µM, 1µM, 10µM) and respective DMSO control. The murine 3D-LTCs were kept in culture for 
48h. For harvest two to three 3D-LTCs were pooled, frozen in liquid nitrogen and subsequently 
stored at -80°C. 
 
4.2.5 Human ex-vivo 3D-Lung tissue cultures  
Human 3D-LTCs were obtained as previously described (Uhl et al. 2015). The freshly excised 
human tissue was filled with warm low gelling agarose (3% by weight (dissolved in DMEM-F12 
supplemented with antibiotics and amphotericin B) via a prominent bronchus using a cannula 
and subsequently cooled for 30 min to allow agarose gelling. Small pieces were then cut into 
500µm thick slices to a speed of 6-10 µm/s, amplitude of 1.2mm and frequency of 100Hz. The 
human 3D-LTCs were cultured in DMEM-F12 complemented with 0.1% FCS and antibiotics (1% 
penicillin/streptomycin and amphotericin B). 3D-LTCs were pre-treated with Nintedanib (1µM) 
or Pirfenidone (500µM) for 1 hour. After adding TGF-β (5ng/ml) the 3D-LTCs were kept in culture 
for 48h. For harvest, two 3D-LTCs were collected and frozen in liquid nitrogen. The samples were 
subsequently stored at -80°C.  
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4.2.6 Fibrotic cocktail  
Human 3D-LTCS/ 4-mm punches were generated as described afore (Uhl et al. 2015, Alsafadi et 
al. 2017) and subjected to a fibrotic cocktail (FC) comprising recombinant TGF-β (5 ng/ml), 
platelet-derived growth factor-AB (PDGF-AB, 5µM), tumor necrosis factor (TNF-α, 10ng/ml) and 
lysophosphatidic acid (LPA, 5µM) or control cocktail (CC) (Alsafadi et al. 2017). After 48h the FC 
was replenished and the 3D-LTCs subjected to Nintedanib (1µM) or Pirfenidone (500µM). 3D-
LTCs/punches were subsequently harvested after 72h for downstream analysis.  





4.2.7 RNA isolation  
For RNA isolation two to three 3D-LTCs were collected, subsequently frozen in liquid nitrogen 
and pulverized using a tissue lyser (2x 30 s at 3,000 rpm). Murine 3D-LTCs were digested using 
RNA lysis buffer containing TCEP for 1h and subsequently incubated with Proteinase K for 10min 
at 55°C. Total RNA was extracted from murine 3D-LTCS using the PeqLap Total RNA kit with minor 
Figure 6: Generation of ex-vivo 3D-lung tissue cultures. The lungs were explanted from wild-type or 
Bleomycin/PBS-treated mice and filled with agarose. The lung lobes were then cut into slices (300µM) with the 
vibratome. Human material was filled with agarose and cut into 500µM thick slices. The 3D-LTCs were cultivated 
up to 48h. (Image modified from Uhl et al.2015) 
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alterations to the manufacturer’s protocol (Uhl et al. 2015).  RNeasy Fibrous tissue kit was utilized 
for RNA isolation from human 3D-LTCs. After being pulverized the human 3D-LTCs were 
incubated with RTT buffer containing DTT for 1h and subsequently incubated with Proteinase K 
for 15min at room temperature.  Peqlab DNA removing columns were applied prior to the RNA 
binding step. After isolation the RNA concentration and quality were determined using the 
NanoDrop spectrophotometer.  
 
4.2.8 cDNA Synthesis  
1µg RNA in 20µl RNase/DNase free water was denatured for 10 minutes at 70°C.  The reverse 
transcription was performed by adding 20µl of the reagent mixture as listed below. After the 
transcription was performed the samples were diluted 1:5 (less if the RNA concentration was 
low). 
 
Table 14: Mastermix for cDNA Synthesis 
Reagent Stock concentration  Final concentration in 40µl Volume  








dNTPs 10mM 1mM 2µl 
Random Hexamers 50µM 5µM 2µl 
RNase-Inhibitor 5 U/µl 0.5 U/µl 1µl 
Reverse Transcriptase 50 U/µl 5 U/µl 2µl 
H2O   1µl 
Final Volume    20µl 
 
 
4.2.9 Quantitative PCR 
Quantitative PCR was conducted using SYBR Green and the LC480 Light Cycler. Gene expression 
analysis of each sample was run in duplicates using 2.5µl of cDNA and 7.5µl master mix per well. 
The master mix compounds and reaction conditions are listed below. Hypoxanthine-
guaninephosphoriboyltransferase (HPRT) for mouse and human was utilized as a reference gene 
in all experiments. Relative gene expression was expressed as ΔCt value (ΔCt = [Ct Hprt] - [Ct gene 
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of interest]). Relative changes upon treatment are displayed as fold change ΔΔCt value (ΔΔCt= 
ΔCt treated-ΔCt control). The primers used are listed above. 
 
 
Table 15: qPCR Mastermix 
Reagent Stock concentration  Final concentration Volume 








H2O   2µl 
cDNA 5ng/µl 12.5ng/µl 2.5µl 
total   10µl 
 
 
Table 16: LC480 Light cycler reaction program 
Steps Repetitions Temperature Time  













  95°C 5 sec 
Melting Curve 1x 60°C 
60°C-95°C  
1 min 




For immunofluorescence analysis 3D-LTCs or 4mm punches were fixed with acetone/methanol 
for 20 min. The 3D-LTCs were subsequently blocked for nonspecific binding with 5% bovine serum 
albumin (BSA) diluted in PBS for 1h at room temperature, followed by incubation with the 
respective primary antibody in PBS comprising 0.1% BSA over night at 4°C. After washing indirect 
immunofluorescence staining was performed by adding the fluorescently labeled secondary 
antibody for 1h.  To visualize cell nuclei DAPI staining was used. The 3D-LTCs were fixated with 
4% formalin for 20 min. After washing the fixated 3D-LTCs were stored at 4°C in PBS containing 
0.1% BSA. Imaging through the 300µm thick z-axis of the 3D-LTCs was performed using the 
LSM710 confocal microscope. 3D reconstruction was done with IMARIS x 64.  
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4.2.11 Immunoblotting 
PmAT II cells or pulverized 3D-LTCs were lysed using Tissue Protein Extraction Reagent (T-PER) 
lysis buffer supplemented with protease and phosphatase inhibitors. The extracted protein was 
clarified from cell detritus by centrifugation (10 000g at 4°C). Protein concentration was 
measured by bicinchoninic acid (BCA) protein assay according to the manufacturer’s protocol. 
After denaturation at 95°C for 5min 15 µg of total protein was loaded with 4x Laemmli loading 
buffer on SDS-polyacrylamide gels, separated by gel electrophoresis and transferred onto 
polyvinylidene difluoride (PVDF) membranes. The SDS polyacrylamid gel concentration (6%-10%) 
was adjusted according to the size of the protein to be detected. The membranes were 
subsequently blocked in 5% nonfat dry milk and incubated with the respective primary antibody 
at 4°C overnight and for 1 h at room temperature. After washing, the membrane was incubated 
with the appropriate HRP-linked secondary antibody for 1 hour at room temperature. The protein 
was visualized using enhanced chemiluminescence and ChemiDoc™ XRS+ system for detection. 
 
4.2.12 Enzyme-linked immunosorbent assay (ELISA) 
Supernatants were obtained from pmAT II cells, murine and human 3D-LTCs. Secreted protein 
concentrations (SP-C, WISP1, IL-6) were assessed by enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s protocol, respectively.  
 
4.2.13 WST-1 based cell toxicity assay 
4-mm punches from murine 3D-LTCS were generated and treated as indicated. After 48h each 
punch was subsequently incubated in 200µl cultivation medium containing 15 μL·mL−1 WST-1 
for 2h. The WST-1 reagent is cleaved into a formazan dye by viable cells. After incubation, the 
punches were removed and the formazan dye formation was quantified using a plate reader at 
450nm. For each treatment a minimum of three punches were measured. The samples were all 
normalized to control containing cultivation medium only. 
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4.2.14 Fluorescence-activated cell sorting (FACS) 
proSPC expression of pmAT II cells was evaluated by flow cytometry. Following cultivation pmAT 
II were fixed and permeabilized using IntraPrepTM Permeabilization Reagent and subsequently 
stained with pro-SPC antibody for 15 min at room temperature. After washing, the cell 
suspension was incubated with secondary antibody Alexa Fluor 488 goat anti-rabbit IgG. After 
another washing step, the cells were re-suspended in FACS Buffer. The amount of 
proSPC+/EpCAM+cells was analyzed using FACS LSRII cell analyzer (BD Bioscience, USA). 
 
4.2.15 Statistical analysis  
All results are presented as mean ± SEM and were analyzed with GraphPad Prism 5 or 8. Statistical 
significance was determined either by paired Student’s t-test or one-sample t-test compared to 
















5.1 Murine ex-vivo 3D-Lung Tissue Cultures (3D-LTCs)   
5.1.1 Characterization of murine ex-vivo 3D-LTCs as fibrosis model  
We initially characterized the murine 3D-LTCs as ex-vivo fibrosis model by investigating pro-
fibrotic gene and protein expression over the culture period of 48h. For this approach we used 
both 3D-LTCs generated from wild-type mice which were subsequently treated with 
Transforming Growth Factor- β1 (TGF-β1) ex-vivo and fibrotic 3D-LTCs from Bleomycin treated 
mice.  
We first sought to evaluate if TGF-β1 as single pro-fibrotic stimulus induces sufficient fibrotic 
changes in 3D-LTCs after 48h. Indeed, fibrotic marker, Fibronectin 1 (Fn1) and Collagen 1 (Col1a1), 
gene expression was significantly upregulated with increased collagen deposition verified by 
immunofluorescence staining (Figure 8B-C). Similarly, pro-inflammatory marker Interleukin-6 (IL-
6) and Wnt-inducible signaling protein 1 (Wisp1) secretion was sufficiently induced by TGF-β1 ex-
vivo (Figure 8D).  









Figure 7: Induction of fibrotic marker expression in ex-vivo murine 3D-LTCs upon TGF-β treatment. (A) Treatment scheme 
of 3D-LTCs with TGF-β or respective control and subsequent downstream analysis. After generation ex-vivo murine 3D-LTC 
were treated with TGF-β and cultivated for 48h. (B) Representative immunofluorescence images of 3D-LTCs subjected to TGF-
β and respective control stained for Collagen I. (C) Fibrotic marker Fn1 and Col1a1 gene expression was investigated by qPCR 
(n=7), paired Student‘s t-test. (D) Wisp1 and IL-6 secretion was determined by ELISA (n = 7), paired Student‘s t-test. *p < 0.05, 
**p < 0.01, ***p < 0.001 
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As a single fibrotic stimulus naturally cannot recapitulate the in-situ development of fibrosis we 
proceeded using fibrotic murine 3D-LTCs. For induction of fibrosis in-vivo mice were 
intratracheally subjected to Bleomycin and sacrificed at day 14 post-installation as the fibrosis is 
known to be established (Jenkins et al. 2017). Morphological analysis showed maintained fibrotic 
lung structure of the newly generated 3D-LTCs with increased collagen and myofibroblast marker 
α-SMA staining (Figure 9B). Simultaneously, E-cadherin (E-Cad), a marker for epithelial cell 
integrity, was decreased (Figure 9B). We further confirmed that 3D-LTCs maintain their fibrotic 
phenotype over the culture time with fibrotic marker gene expression, Fn1 and Col1a1, being 
significantly upregulated compared to PBS control after 48h of culture (Figure 9C). Similarly, 
collagen secretion, being assessed by Western Blotting, was significantly increased after 48h 
(Figure 9D). We further observed increased IL-6 and Wisp1 secretion as a sign of ongoing 
inflammation and activation of pro-fibrotic pathways after 48h of culture (Figure 9E-F). 
Therefore, major hallmarks of fibrosis such as increased ECM deposition, sustained inflammation 
and impaired epithelial cell integrity were retained in fibrotic 3D-LTCs proving it to be feasible for 

























5.1.2 Nintedanib and Pirfenidone dose-dependently inhibit fibrotic marker expression in 
murine ex-vivo 3D-LTCs  
Next, we sought to evaluate whether Nintedanib and Pirfenidone inhibit the pro-fibrotic 
phenotype in both murine 3D-LTCs subjected to TGF-β1 ex-vivo and fibrotic 3D-LTCs from 
Bleomycin treated mice. For this purpose, we assessed fibrotic and inflammatory marker gene 
and protein expression upon drug treatment. Prior to drug treatment we performed WST-1 assay 
and found the cell proliferation to be reduced upon higher drug concentrations (Nintedanib: 
10µM; Pirfenidone: 2.5.mM) which led to decision to hereafter precede with the lower, more 
physiological concentrations for both drugs and that have been used in in-vitro studies before 
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Figure 8: Maintenance of pro-fibrotic phenotype of murine 3D-LTCs during cultivation. (A) Scheme of fibrotic 3D-LTCs 
generation from Bleomycin treated mice. (B) Representative immunofluorescence images of fibrotic 3D-LTCs and PBS control 
stained for Collagen I, α-SMA and E-Cadherin. (C) Fibrotic marker Fn1 and Col1a1 gene expression in fibrotic 3D-LTCs and  PBS 
control was investigated by qPCR (n=7), paired Student‘s t-test. (D) Collagen I secretion of fibrotic 3D-LTCs and PBS control 
was assessed by Western blot (n=6), paired Student‘s t-test. (D, E) WISP1 and IL-6 secretion of fibrotic 3D-LTCs and PBS was 



































































Thus, we found TGF-β1 induced fibrotic marker, Fn1 and Col1a1, gene and protein expression 
decreased upon Nintedanib and Pirfenidone treatment in a dose dependent manner (Figure 10A-
B). Similarly, inflammatory marker IL-6 secretion was inhibited by both Nintedanib and 
Pirfenidone. Noteworthy, Pirfenidone significantly diminished IL-6 secretion at 100µM but not at 












We further assessed the effectiveness of Nintedanib and Pirfenidone treatment in already 
established fibrosis using fibrotic 3D-LTCs derived from Bleomycin treated mice. Consistently, we 
observed a dose-dependent downregulation of fibrotic marker gene expression by both 
Nintedanib and Pirfenidone (Figure 11A). We observed a trend of Nintedanib but not for 



































































































Figure 9: Effect of Nintedanib and Pirfenidone on fibrotic marker expression in TGF-β treated 3D-LTCs. (A) Murine 3D-LTCs 
were pretreated with Nintedanib and Pirfenidone for 1h. After adding TGF-β the 3D-LTCs were cultured for 48h. Fibrotic 
marker Fn1 and Col1a1 gene expression was investigated by qPCR (n=3-6), one-sample t-test compared to the theoretical 
value of 0. (B) Representative immunofluorescence images of TGF-β treated 3D-LTCs and Nintedanib or Pirfenidone and 
stained for Collagen I. (C) IL-6 secretion was measured by ELISA (n = 5), one-sample t-tests compared to the theoretical value 
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5.1.3 Double treatment with Nintedanib and Pirfenidone shows an additive effect in 
downregulating fibrotic marker expression in fibrotic murine ex-vivo 3D-LTCs 
Pirfenidone and Nintedanib presumably exert their anti-fibrotic action via different targets 
indicating that co-treatment might have a synergistic effect, thus improving the overall outcome 
in IPF patients (Vancheri et al. 2018). For proof of concept, we co-treated fibrotic murine 3D-LTCs 
with Nintedanib (0.1 µM) and Pirfenidone (100µM) for 48h. Notably, the double treatment 
showed an additive effect significantly downregulating Fn1 gene expression compared to 
Nintedanib (0.1 µM) and Pirfenidone (100µM) alone, analyzed by qPCR. A similar trend was 






Figure 10: Effect of Nintedanib and Pirfenidone on fibrotic marker expression in fibrotic 3D-LTCs. (A) Fibrotic murine 3D-
LTCs were subjected to Nintedanib or Pirfenidone and cultured for 48h. Fibrotic marker Fn1 and Col1a1 gene expression was 
investigated by qPCR (n=5-6), one-sample t-test compared to the theoretical value of 0. (B) Collagen I secretion of fibrotic 3D-
LTCs subjected to Nintedanib (1µM) or Pirfenidone (500µM) was assessed by Western blot (n=4), paired Student‘s t-test. *p 






























































































































Altogether, the data presented here confirms the findings of previous in-vivo investigations of 
the anti-fibrotic action of Nintedanib and Pirfenidone and proves ex-vivo 3D-LTCs to be a suitable 
tool for preclinical drug testing. 
 
5.1.4 Nintedanib and Pirfenidone differentially affect epithelial cell function in murine ex-vivo 
3D-LTCs 
Impaired epithelium is known to play a crucial role in the pathogenesis of IPF. However, while 
most studies on the anti-fibrotic action of Nintedanib and Pirfenidone have been performed on 
fibroblasts, little is known about these drugs affecting epithelial cell function. Therefore, we next 
evaluated the distinct effect of Nintedanib and Pirfenidone on alveolar epithelial type II cells in 
TGF-β treated 3D-LTCs. TGF-β1 is known to induce epithelial cell apoptosis and EMT in fibrosis 
(Schuster and Krieglstein 2002, Xu, Lamouille and Derynck 2009). We first analyzed AT II cell 
marker pro-SPC protein expression by Western Blotting and found it to be decreased upon TGF-
β treatment (Figure 13). Notably, we observed a trend of Nintedanib (1µM) and Pirfenidone 
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Col1a1 
Figure 11: Double treatment with Nintedanib and Pirfenidone in fibrotic 3D-LTCs. Fibrotic murine 3D-LTCs were subjected 
to Nintedanib (0.1µM), Pirfenidone (100µM) or double treatment (Nintedanib (0.1µM) + Pirfenidone (100µM)) for 48h. 
Fibrotic marker Fn1 and Col1a1 gene expression was assessed by qPCR (n=5-6), one-sample t-tests compared to the 

























Along with this, Wisp1, a pro-fibrotic mediator mainly secreted by altered epithelium in fibrosis, 
was significantly inhibited by both Nintedanib and Pirfenidone in 3D-LTCs upon TGF-β1 
treatment, as analyzed by ELISA.  Nintedanib showed sufficient downregulation at 0.1 µM with 
no additive effect at 1µM potentially indicating target saturation. Again, Pirfenidone significantly 
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Figure 13: Effect of Nintedanib and Pirfenidone on epithelial cell function in TGF-β1 treated 3D-LTCs. (A, B) Murine 3D-LTCs 
were pretreated with Nintedanib and Pirfenidone for 1h, subsequently subjected to TGF- β and cultured for 48h. WISP1 
secretion was determined by ELISA (n=3-4), one-sample t-test compared to the theoretical value of 1. *p < 0.05, **p < 0.01 
Figure 12: Effect of Nintedanib and Pirfenidone on proSP-C protein expression in TGF-β treated 3D-LTCs. Murine 3D-LTCs 
were pretreated with Nintedanib (1µM) and Pirfenidone (500µM) for 1h, subsequently subjected to TGF-β and cultured for 
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We further confirmed our findings using fibrotic murine 3D-LTCs.  Consistently, we observed 
Nintedanib significantly increasing AT II cell marker pro-SPC protein expression and secretion. 
Notably, Pirfenidone failed to sufficiently induce epithelial cell marker expression in fibrotic 3D-









Similarly, pro-fibrotic mediator Wisp1 was decreased upon Nintedanib but not Pirfenidone 






































Figure 14: Effect of Nintedanib and Pirfenidone on proSP-C protein expression in fibrotic 3D-LTCs. Fibrotic murine 3D-LTCs 
were treated with Nintedanib (1µM) and Pirfenidone (500µM) for 48h. Western blot analysis of pro-SPC expression (n=6), 
paired Student’s t-test.  *p < 0.05 
Figure 15: Effect of Nintedanib and Pirfenidone on epithelial cell function in fibrotic 3D-LTCs. Fibrotic murine 3D-LTCs were 
treated with Nintedanib (1µM) and Pirfenidone (500µM) for 48h. (A) SP-C secretion and (B) WISP1 secretion was assessed by 


















































































































5.2 Primary murine alveolar type II (pmAT II) cell monoculture  
5.2.1 Nintedanib and Pirfenidone inhibit fibrotic marker expression in pmAT II cells 
Based on our findings in 3D-LTCs we further sought to delineate the effects of Nintedanib and 
Pirfenidone on epithelial cell function using primary murine alveolar type (pmAT) II cell 
monoculture. For this approach we utilized both pmAT II cells derived from wild-type mice and 
subsequently subjected to TGF-β1 in-vitro and fibrotic pmAT II cells from Bleomycin treated mice. 
The model of cultivating pmAT II cells in-vitro itself has been widely used to recapitulate repair 
processes upon injury with pmAT II cells differentiating to AT I cells during cultivation time (Mutze 
et al. 2015, Demaio et al. 2009). Alveolar epithelial cells are known to exhibit a pro-fibrotic 
phenotype upon TGF-β1 with losing epithelial and subsequently acquiring mesenchymal cell 
properties (Ding et al. 2017). Thus, we first confirmed fibrotic marker, Fn1 and Col1a1, gene 







Both Nintedanib (0,1µM, 1µM) and Pirfenidone (100µM, 500µM) subsequently decreased TGF-
β1 induced fibrotic marker gene expression (Figure 18A). On protein level Nintedanib, but not 





Figure 16: Induction of fibrotic marker expression in pmAT II upon TGF-β treatment. PmAT II were treated with TGF-β for 
48h. Fibrotic marker Fn1 and Col1a1 gene expression in control and TGF-β treated pmAT II cells (n=9), paired Student‘s t-test. 




















































Apart from the anti-fibrotic action of Nintedanib and Pirfenidone both drugs significantly 
decreased pro-inflammatory marker IL-6 secretion in pmAT II cells upon TGF-β treatment. Using 
two different concentrations for Nintedanib (0.1µM, 1µM) and Pirfenidone (100µM, 500µM), we 
observed a dose dependent effect for Nintedanib. Notably, both Pirfenidone concentrations 
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Figure 18: Effect of Nintedanib and Pirfenidone on inflammatory marker IL-6 secretion in TGF-β treated pmAT II cells. PmAT 
II cell were pretreated with Nintedanib (0.1µM, 1µM) or Pirfenidone (100µM, 500µM) for 1h, subsequently subjected to TGF-
β and cultured for 48h. IL-6 secretion was determined by ELISA (n=3-7), one-sample t-test compared to the theoretical value 
of 1. **p < 0.01, ***p < 0.001 
Figure 17: Effect of Nintedanib and Pirfenidone on fibrotic marker expression in TGF-β treated pmAT II cells. (A, B) PmAT II 
cell were pretreated with Nintedanib (A: 0.1µM, 1µM; B: 1µM) or Pirfenidone (A: 100µM, 500µM; B: 500µM) for 1h, 
subsequently subjected to TGF-β and cultured for 48h. (A) Fibrotic marker Fn1 and Col1a1 gene expression was investigated 
by qPCR (n=3-5), one-sample t-test compared to the theoretical value of 0. (B)  Western blot analysis of collagen I expression 
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We further evaluated our findings using fibrotic pmAT II cells derived from Bleomycin treated 
mice. We first confirmed pmAT II cells to retain their pro-fibrotic phenotype with increased 






Nintedanib (1µM) and Pirfenidone (500µM) subsequently diminished the pro-fibrotic phenotype 







5.2.2 Nintedanib and Pirfenidone differentially affect epithelial cell marker expression in pmAT 
II cells 
We previously confirmed alveolar epithelial cell function to be affected upon Nintedanib and 
Pirfenidone treatment in ex-vivo 3D-LTCs. To further elucidate, if these drugs directly affect 
epithelial cell function or this effect is mediated by other cell types, we treated pmAT II cells 
either with Nintedanib or Pirfenidone upon a fibrotic stimulus and tested for alveolar type II and 
I cell marker gene expression, Sftpc (Surfactant protein C), Nkx2.1 (NK2 homeobox 1) and T1α 









   
Col1a1 
 
Figure 20: Effect of Nintedanib and Pirfenidone on fibrotic marker expression in fibrotic pmAT II cells. Fibrotic pmAT II cells 
were treated with Nintedanib (1µM) or Pirfenidone (500µM) for 48h. Fibrotic marker Fn1 and Col1a1 gene expression was 
assessed by qPCR (n=9), paired Student‘s t-test. *p < 0.05, **p < 0.01 
Figure 19: pmAT II derived from Bleomycin treated mice retain their pro-fibrotic phenotype in culture. Fibrotic marker Fn1 


















































































































significantly downregulated by TGF-β in pmAT II cells. Notably, AT I cell marker T1α remained 





Nintedanib subsequently increased both AT II cell marker Sftpc and AT I cell marker T1α gene 
expression along with regulatory genes Nkx2.1 and Hopx. Pirfenidone showed a trend for 
upregulating AT II cell marker Sftpc and Nkx2.1 expression. However, only AT I cell marker T1α 









We next performed fluorescence-activated cell sorting (FACS) analysis for SPC positivity of pmAT 
II cells subjected to Nintedanib treatment. Noteworthy, overall SPC-positive cells were strongly 
decreased after four days of cultivation. This is most likely due to profound phenotypic changes 
as AT II cells both transdifferentiate to AT I cells and acquire a mesenchymal phenotype during 
Figure 22: Effect of Nintedanib and Pirfenidone on epithelial cell marker gene expression in TGF-β treated pmAT II cells. 
PmAT II cell were pretreated with Nintedanib (1µM) or Pirfenidone 500µM) for 1h, subsequently subjected to TGF-β and 
cultured for 48h. Epithelial cell marker Sftpc, Nkx2.1, T1α and Hopx gene expression was investigated by qPCR (n=3-6), one-
sample t-test compared to the theoretical value of 0. *p < 0.05, ***p < 0.001 
Figure 21: TGF-β treatment affecting epithelial cell marker expression in pmAT II cell monoculture.  PmAT II were treated 
with TGF-β for 48h. Epithelial cell marker Sftpc and T1α gene expression was investigated by qPCR (n=9), paired Student‘s t-














































































































































































culture subsequently loosing AT II cell properties. Nevertheless, we observed a trend of 








We further determined the impact of Nintedanib and Pirfenidone on pro-fibrotic mediator Wisp1 
mainly secreted by altered epithelium using ELISA and found it to be decreased upon drug 






Further evaluating our findings in pre-injured pmAT II cells we used fibrotic pmAT II cells derived 
from Bleomycin treated mice.  We first verified that the epithelial injury was retained after 48h 
of culture with decreased Sftpc gene expression compared to PBS control. Notably, T1α 
expression was increased indicating an attempted repair by AT II cells transdifferentiating to AT 
I cells (Figure 25). 
Pirfenidone [mM] 100 500 
TGF-β 0.1 1 TGF-β Nintedanib [µM] 
Figure 23: Effect of Nintedanib and Pirfenidone on epithelial cell marker protein expression in TGF-β treated pmAT II cells. 
PmAT II cells were pretreated with Nintedanib (1µM) or Pirfenidone 500µM) for 1h, subjected to TGF-β and cultured for 48h. 
PmAT II cells were analyzed for SPC positivity using fluorescence-activated cell sorting (FACS) (n=3), paired Student‘s t-test.       
Figure 24: Effect of Nintedanib and Pirfenidone on Wisp1 secretion in TGF-β treated pmAT II cells. PmAT II cells were 
pretreated with Nintedanib (0,1 µM, 1µM) or Pirfenidone (100µM, 500µM) for 1h, subjected to TGF-β and cultured for 48h. 
Wisp1 secretion was investigated by ELISA (n=3-7), one-sample t-tests compared to the theoretical value of 1. *p < 0.05, ***p 
< 0.001 
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Similar to our previous findings, Nintedanib significantly increased AT II cell marker Sftpc and 
Hopx with a comparable trend for Nkx2.1 and T1α. Pirfenidone solely affected AT I cell marker 
T1α and Hopx gene expression (Figure 26). Overall, Nintedanib, but not Pirfenidone restored AT 











Figure 26: Effect of Nintedanib and Pirfenidone on epithelial cell marker expression in fibrotic pmAT II cells. Fibrotic pmAT 
II cells were treated with Nintedanib (1µM) or Pirfenidone (500µM) and cultured for 48h. Epithelial cell marker Sftpc, Nkx2.1, 
T1α and Hopx gene expression was investigated by qPCR (n=3), paired Student‘s t-test. *p < 0.05, **p < 0.01, ***p < 0.001 
Figure 25: Epithelial cell injury is retained in fibrotic primary murine (pm) AT II cells during culture. Fibrotic pmAT II were 
cultured for 48h. Epithelial cell marker Sftpc and T1α gene expression in fibrotic pmAT II cells and PBS control was investigated 























































































































































































































5.3 Human ex-vivo 3D-LTCs 
5.3.1 Nintedanib and Pirfenidone don’t significantly inhibit fibrotic marker expression in 
human ex-vivo 3D-LTCs  
While most studies on the anti-fibrotic action of both Nintedanib and Pirfenidone have been 
conducted on either isolated cells or in animals, little is known about their actual activity within 
the intact human system. In this context, human 3D-LTCs represent a valuable tool to mimic the 
in-situ situation as close as possible. Here we used human 3D-LTCs derived from lung cancer 
resection either treated with TGF-β alone or a fibrotic cocktail consisting of TGF-β, TNF-α, LPA 
and PDGF α/β.  
We first confirmed both FN1 and COL1A1 gene and protein expression to be sufficiently 
upregulated upon TGF-β treatment in the human 3D-LTCs. Interestingly, the increase of fibrotic 
marker gene expression highly differed between the patient samples suggesting different 




















































Figure 27: Induction of fibrotic marker expression in ex-vivo human 3D-LTCs upon TGF-β treatment. Human 3D-LTCs were 
subjected to TGF- β for 48h. (A) Fibrotic marker FN1 and COL1A1 gene expression in human 3D-LTCs treated with TGF-β and 
respective control was investigated by qPCR (N=9), paired Student‘s t-test. (B) Representative immunofluorescence images 
of human 3D-LTCs treated with TGF-β and respective control stained with Fibronectin. ***p < 0.001 
TGF-β ctrl 
DAPI FN1 
DAPI COLLAGEN I 
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However, neither Nintedanib nor Pirfenidone were able to significantly inhibit the pro-fibrotic 
marker gene expression following TGF-β treatment. Nintedanib solely showed a trend towards 






In respect of the limited availability of IPF tissue we next used a fibrotic cocktail that has 
previously been established in our lab mimicking “early fibrotic like” changes in human 3D-LTCs. 
After the induction of an “early fibrosis like” phenotype within the first 48h of culture we 
subsequently treated the 3D-LTCs with either Nintedanib (1µM) or Pirfenidone (500µM) for 72h 
before harvesting. The detailed treatment scheme is depicted in Figure 29.  
 




Figure 29: Treatment scheme with fibrotic cocktail (FC) or control cocktail (CC) and Nintedanib (1µM) or Pirfenidone 
(500µM) and subsequent downstream analysis.  Human 3D-LTCs were subjected to FC or CC. After 48h FC or CC was renewed 
and Nintedanib or Pirfenidone were added. Human 3D-LTCs were harvested after 120h and downstream analysis was 
performed. 
Figure 28: Ex-vivo effect of Nintedanib and Pirfenidone on fibrotic gene expression in TGF-β treated human 3D-LTCs. Human 
3D-LTCs were pretreated with Nintedanib (1µM) or Pirfenidone (500µM) for 1 h, subsequently subjected to TGF-β and 




































































We first confirmed the early fibrosis like changes after 120 hours of cultivation by fibrotic marker 
FN1 and COL1A1 gene expression analysis and immunofluorescence staining visualizing 
fibronectin accumulation in the 3D-LTCs.  Indeed, we observed a significant increase of FN1 gene 








Subsequent treatment with Nintedanib and Pirfenidone did not significantly decrease FN1 and 
COL1A1 gene expression in FC- treated human 3D-LTCs.  However, a trend of Nintedanib and 









Control Cocktail (CC) A B 
Figure 31: Ex-vivo effect of Nintedanib and Pirfenidone on fibrotic cocktail induced “early fibrosis like changes” in human 
3D-LTCs. Fibrotic marker FN1 and COL1A1 gene expression was investigated by qPCR (N=4), one-sample t-test compared to 
the theoretical value of 0.  
Figure 30: Fibrotic cocktail induces fibrotic marker gene and protein expression in human 3D-LTCs ex-vivo. (A) Fibrotic 
marker FN1 and COL1A1 gene expression was investigated by qPCR (N=3), paired Student‘s t-test. (B) Representative 
immunofluorescence images of punches subjected to FC and respective control and stained for Fibronectin. Scale bar 


































































Pirfenidone + - + + - + 
DAPI		FN1 







































5.3.2 Nintedanib and Pirfenidone differentially influence epithelial cell function in human ex-
vivo 3D-LTCs upon TGF-β treatment 
We next sought to investigate the differential effects of Nintedanib and Pirfenidone on epithelial 
cell functioning in human 3D-LTCs. We first analyzed transcript levels of epithelial cell marker 
upon TGF-β treatment in human 3D-LTCs.  Notably, TGF-β alone was not able to sufficiently 






Nintedanib subsequently increased epithelial cell integrity marker CDH1 and ZO1 expression 
upon TGF-β treatment.  A similar trend was observed for SFTPC and NKX2.1 gene expression. On 
protein level pro-SPC secretion was induced by Nintedanib. On the contrary, Pirfenidone neither 

































































Figure 32: Effect of TGF-β on epithelial cell marker expression in human 3D-LTCs. Human 3D-LTCs were subjected to TGF- β 








































































Figure 33: Ex-vivo effect of Nintedanib and Pirfenidone on epithelial cell function in TGF-β treated human 3D-LTCs. Human 
3D-LTCs were pretreated with Nintedanib (1µM) or Pirfenidone (500µM) for 1 h, subsequently subjected to TGF-β and 
cultured for 48h. (A) Epithelial cell marker CDH1, ZO1, SFTPC, NKX2.1 and T1α gene expression was investigated by qPCR 


























































   
   




















































































































































5.3.3 Nintedanib and Pirfenidone affecting epithelial cell function in human ex-vivo 3D-LTCs 
subjected to the Fibrotic Cocktail 
Because TGF-β solely was insufficient to derange epithelial cell integrity in human 3D-LTCs we 
next utilized human 3D-LTCs treated with the fibrotic cocktail (FC). Alsafadi et al. previously 
demonstrated epithelial cell injury to be induced upon the fibrotic cocktail after 120 h of culture 
(Alsafadi et al. 2017). Similarly, we showed epithelial cell marker gene expression to be reduced 
upon FC and subsequently observed a trend for both Nintedanib and Pirfenidone to restore 












We further checked for corresponding epithelial cell marker protein expression and found both 
SPC-secretion in the supernatant and expression as evaluated by immunofluorescence staining 
increased in human 3D-LTCs upon Nintedanib treatment. Similary, general alveolar epithelial 
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Figure 34: Ex-vivo effect of Nintedanib and Pirfenidone on epithelial cell marker gene expression in fibrotic cocktail (FC) 
treated human 3D-LTCs. Epithelial cell marker CDH1, ZO1, SFTPC, NKX2.1 and T1α gene expression was investigated by qPCR 




























































Figure 35: Ex-vivo effect of Nintedanib on epithelial cell marker protein expression in fibrotic cocktail (FC) treated human 
3D-LTCs. (A) Pro-SPC secretion was determined by ELISA. (N=6), paired Student‘s t-test. (B) E-CADHERIN protein expression 
was investigated by Western blot (N=3), one-sample t-test compared to theoretical value of 1. (C) Representative 
immunofluorescence images of pro-SPC of human 3D-LTCs treated with FC and Nintedanib and respective control. Scale bar 































































































IPF is a fatal interstitial lung disease characterized by unremitting extracellular matrix 
accumulation which results in the irreversible destruction of the lung architecture and impaired 
gas exchange in patients. The pathogenesis of IPF is incompletely understood. However, over the 
past decades the concept of an “epithelial-driven disorder” emerged, in which repetitive 
epithelial cell injury and genetic predisposition lead to the formation of a dysfunctional epithelial 
cell phenotype, which then initiates fibroblast activation and ECM accumulation (Selman and 
Pardo 2020). Nintedanib and Pirfenidone, two recently approved drugs and a major 
breakthrough in the treatment of IPF, decelerate but not stop disease progression. Therefore, 
novel therapeutic options for the treatment of IPF are needed. In this process, a better 
understanding of Nintedanib and Pirfenidone affecting epithelial cell function and how this 
possibly contribute to the general anti-fibrotic action of these drugs is key and might ultimately 
reveal new targets for alternative therapeutic approaches. Therefore, the here presented data is 
of special interest as most mechanistic studies solely focused on how Nintedanib and Pirfenidone 
potentially affect fibroblast (Wollin et al. 2015, Hostettler et al. 2014, Knuppel et al. 2017), but 
not epithelial cell function.   
In the present study we report that Nintedanib and Pirfenidone differentially affect alveolar 
epithelial cell function, with Nintedanib significantly inducing alveolar type II cell marker and 
interfering with the aberrant epithelial-mesenchymal-crosstalk (by reducing WISP1 secretion) in 
both 3D-LTCs and pmAT II cell monoculture. We demonstrated that Nintedanib and Pirfenidone 
exert their anti-fibrotic action in murine 3D-LTCs by inhibiting fibrotic and inflammatory marker 
expression and thus, proving the murine 3D-LTCs to be a valuable tool for testing the mechanism 
of action of anti-fibrotic drugs. We further demonstrated that Nintedanib affecting epithelial cell 
function had a more conserved effect than downregulating pro-fibrotic gene expression in 




6.1 The applicability of ex-vivo 3D-LTCs for pre-clinical drug testing 
At the onset of our study, we aimed to evaluate the ex-vivo 3D-LTCs as suitable model for 
preclinical drug testing in the context of fibrosis. Ex-vivo 3D-LTCs show distinct advantages 
compared to the traditional 2D culture. Cells undergoing cell isolation and being plated on supra-
physiological stiff surfaces naturally behave differently than in the in-vivo situation which 
complicates the translation of mechanistic findings in-vitro into efficient therapies for patients 
(Bailey et al. 2018, Uhl et al. 2015). Thus, 90% of all novel compounds fail in clinical trials, most 
of them in phase II highlighting the need for more accurate preclinical models (Perry and 
Lawrence 2017). In contrast to in-vitro monoculture 3D-LTCs resemble the in-vivo situation more 
closely retaining the cellular and structural complexity including cell-to-cell and cell-to-matrix 
interactions. Cell viability and function such as ciliary beating was shown to be maintained up to 
7 days in culture (Uhl et al. 2015).  Additionally, the use of murine 3D-LTCs in particular reduces 
the overall animal numbers needed for experimentation. However, the complexity of the in-vivo 
situation can still not be fully emulated by ex-vivo 3D-LTCs lacking air-liquid-interfaces within the 
alveoli, the recruitment of immune and progenitor cells via the bloodstream and the cyclic stretch 
deflection while breathing mechanically stimulating the cells (Uhl 2015, Lehmann et al. 2018, 
Zscheppang et al. 2018). Additionally, the cutting process along with potential hypoxia in the 
middle of the slices, are possible stressors altering cellular behavior (Neuhaus et al. 2017). 
Considering these limitations, animal models for testing compounds within a living organism are 
still pivotal (Jenkins et al. 2017).  Nevertheless, as animal models cannot fully resemble human 
disease especially the usage of human 3D-LTCs is a unique possibility to perform preclinical drug 
validation within an intact human microenvironment. However, a major challenge of human 
tissue remains the inter-individual variability of the samples together with the complexity of the 
model itself making a proper data interpretation more complicated. Additionally, most human 
tissue is obtained from lung cancer surgeries and thus, any finding can be potentially altered due 
to the underlying disease (Zscheppang et al. 2018). Therefore, the acquired data needs to be 
evaluated in respect of the systems limitations and confirmed by complementary approaches in 
order to improve result precision and accurately anticipate drug responsiveness in patients 
(Zscheppang et al. 2018). 
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Previous studies demonstrated the applicability of human and murine 3D-LTCs for preclinical 
drug testing investigating the effect of caffeine in murine fibrotic 3D-LTCs and PI3 kinase/mTOR 
inhibitor in human IPF 3D-LTCs (Tatler et al. 2016, Mercer et al. 2016). Especially, fibrotic 3D-LTCs 
derived from Bleomycin treated mice represent a suitable tool for ex-vivo drug testing in already 
established fibrosis. Tatler et al. showed that 3D-LTCs obtained from Bleomycin treated mice 
retain their fibrotic properties over the culture time of 5 days (Tatler et al. 2016). Similar to these 
findings, we observed both mesenchymal and inflammatory marker to be increased after 48h of 
culture in fibrotic 3D-LTCs. Within 7 days of culture, we found extracellular matrix compounds, 
Fn1 and Col1a1, even more elevated indicating that fibroblasts remain viable and continue to 
deposit extracellular matrix proteins in culture. On the contrary alveolar type II cell marker Sftpc 
was decreased suggesting the epithelial injury upon bleomycin treatment was retained during 
culture. Along with this, Wisp1, a WNT-target gene and pro-fibrotic mediator mainly secreted by 
altered epithelium (Konigshoff et al. 2009), was upregulated, thus proving epithelial functioning 
with recapitulation of developmental pathways to be still impaired in culture. Overall, it can be 
assumed, that pre-injured 3D-LTCs not only continue to exhibit pro-fibrotic hallmarks during 
culture, but the culture itself induces pro-fibrotic changes. In fact, prolonged culture of precision 
cut liver slices was proposed as a model of early fibrosis with increased ECM deposition (Westra 
et al. 2014). However, these pro-fibrotic changes also limit cell functionality and viability of 3D-
LTCs in culture and therefore restrict overall culture duration (Uhl et al. 2015, Umachandran, 
Howarth and Ioannides 2004).  Interestingly, Bailey et al. demonstrated murine 3D-LTCs to 
remain viable for at least 21 days after being encapsulated in hydrogel and replenished with cell-
adhesive components, thus supporting the longevity of epithelial cells while inhibiting fibroblast 
overgrowth in culture (Bailey et al. 2020). Indeed, it supports the notion that the alveolar 
epithelium is crucial to sustain tissue homeostasis in-situ and ex-vivo. 
For a more mechanistic approach we additionally sought to investigate the distinct anti-fibrotic 
action of Nintedanib and Pirfenidone on TGF-β as a single pro-fibrotic stimulus in ex-vivo 3D-LTCs. 
For this purpose, we first evaluated the impact of TGF-β1 on murine and human ex-vivo 3D-LTCs. 
TGF-β1 is known to be a main driver of fibrosis development secreted by alveolar epithelial cells 
and fibroblasts (Fernandez and Eickelberg 2012a). We found mesenchymal marker to be 
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significantly increased upon TGF-β1 in both human and murine 3D-LTCs. Similarly, alveolar type 
II cell marker SP-C was decreased with TGF-β inducing epithelial cell apoptosis and epithelial- 
mesenchymal-transition (EMT) (Ding et al. 2017) in 3D-LTCs ex-vivo. Notably, we observed a high 
expression variability of pro-fibrotic genes, such as FN1 and COL1A1, on baseline and after TGF-
β1 induction between each patient sample. It again highlights the great inter-individual 
differences that need to be taken into account.  
TGF-β as a single fibrotic stimulus cannot induce profound structural changes in ex-vivo 3D-LTCs 
as highlighted by immunofluorescence staining. Therefore, also in respect of the limited 
availability of IPF tissue we further used a model for “early fibrosis like changes” in human ex-
vivo 3D-LTCs that was previously established in our lab. Alsafadi et al. showed pro-fibrotic and 
inflammatory mediators to be upregulated along with enhanced ECM deposition and alveolar 
epithelial cell injury upon a fibrotic cocktail (FC) treatment comprising TGF-β, TNF-α, LPA and 
PDGF α/β (Alsafadi et al. 2017). However, myofibroblast marker α-SMA was not sufficiently 
increased indicating that fibroblast to myofibroblast transdifferentiation, a major hallmark of IPF 
pathogenesis, was not induced by fibrotic cocktail treatment ex-vivo. The authors proposed the 
lack of profound ECM remodeling with increased matrix stiffening in the non-ILD tissue to be the 
reason for the insufficient myofibroblast differentiation. Indeed, TGF-β induced (myo-) fibroblast 
activation  was shown to be highly dependable on matrix stiffness (Marinković, Liu and 
Tschumperlin 2013).  Interestingly, we similarly observed in fibrotic murine 3D-LTCs α-SMA 
protein expression to be still retained when the difference on gene expression level was already 
diminished. This might be indicative for an insufficient fibroblast to myofibroblast 
transdifferentiation in ex-vivo 3D-LTCs independent of matrix stiffness. However, further 
investigations are needed to support this notion. 
Taken together both murine and human fibrotic 3D-LTCs recapitulate certain characteristics of 
fibrosis such as the upregulation of pro-inflammatory and pro-fibrotic cytokines, prolonged 
alveolar epithelial cell injury along with impaired epithelial-mesenchymal crosstalk and increased 
extracellular matrix deposition in culture. However, the two systems mimic an acute state of the 
disease. Bleomycin induced lung fibrosis in mice, in particular, was shown to be partially 
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reversible within weeks (Moeller et al. 2008).  In fact, developing IPF as a patient is a process of 
decades with innumerable co-activated pathways and interactions leading to the irreversible 
destruction of the lung architecture. Therefore, both models naturally fail to fully recapitulate 
the complexity of disease pathogenesis in patients. Nevertheless, taken these limitations into 
account, both murine and human fibrotic 3D-LTCs can be valuable complementary approach in 
pre-clinical drug testing. 
 
6.2 Investigating the effect of Nintedanib and Pirfenidone on pro-fibrotic marker expression in 
murine and human ex-vivo 3D-LTCs  
6.2.1 Nintedanib and Pirfenidone inhibit fibrotic marker expression in murine ex-vivo 3D-LTCs 
In-vitro monoculture was previously used to single out the distinct impact of Nintedanib and 
Pirfenidone on diseased lung fibroblasts as main contributor of excessive ECM deposition (Conte 
et al. 2014, Knuppel et al. 2017, Lehtonen et al. 2016, Nakayama et al. 2008, Wollin et al. 2015). 
However, a recent study showed only little concordance when comparing gene expression 
profiles of lung fibroblasts derived from Pirfenidone treated individuals with IPF fibroblasts 
treated with Pirfenidone in-vitro (Kwapiszewska et al. 2018). This fact highlights the complexity 
of the anti-fibrotic action of both Nintedanib and Pirfenidone in-situ and the need of more 
accurate models to resemble the in-vivo setting. In this context, 3D-LTCs retaining much of the 
cellular and structural complexity of the lung tissue can be of special interest. Here we report 
that Nintedanib and Pirfenidone reduce pro-fibrotic marker gene expression both upon TGF-β1 
treatment and in fibrotic murine 3D-LTCs in a dose dependent manner. Additionally, both drugs 
inhibited inflammatory marker IL-6 secretion and functional collagen secretion in murine 3D-
LTCs. Notably, we observed Nintedanib in therapeutically relevant concentrations (0.1µM, 1µM) 
to be more effective in decreasing pro-fibrotic marker gene expression and secretion compared 
to Pirfenidone. In fact, Pirfenidone exerted significant anti-fibrotic effects at 2.5mM. This effect 
is presumably related to cell toxicity of the DMSO solvent or Pirfenidone itself with decreasing 
cell proliferation. Moreover, Pirfenidone concentration of 2.5mM is much higher than the plasma 
concentration of Pirfenidone achieved in IPF patients after therapeutic dosing (Wollin 2015). 
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Similar observations have been made by Knüppel et al. with Nintedanib being more effective in 
downregulating pro-fibrotic marker expression in IPF fibroblasts (Knuppel et al. 2017). 
Interestingly, despite of these in-vitro findings both Nintedanib and Pirfenidone show a similar 
efficacy in the real-life treatment of IPF patients although much higher therapeutic dosing is 
required for Pirfenidone (Bargagli et al. 2018, Cottin 2017). This discrepancy of clinical 
effectiveness and experimental results might be due to methodic limitations of both in-vitro and 
ex-vivo cell culture and/or the selection of readouts and time points of analysis. For instance, 
Pirfenidone is partly degraded into its metabolites in-situ which were also shown to exhibit an 
anti-fibrotic activity (Togami et al. 2013). Moreover, Pirfenidone treatment in IPF patients was 
demonstrated to induce profound alterations in inflammatory processes (Kwapiszewska et al. 
2018). However, the potential impact of  Pirfenidone metabolites and on circulating immune cells 
that are known to contribute to fibrogenesis (Fernandez et al. 2016) cannot be fully recapitulated 
using fibroblast monoculture or ex-vivo 3D-LTCs. This underlines again the intricate anti-fibrotic 
action of Nintedanib and Pirfenidone in-situ and might explain the differences of the actual 
clinical effectiveness of both drugs and our results. 
 
6.2.2 Double treatment with Nintedanib and Pirfenidone show a synergistic effect in 
downregulating pro-fibrotic marker expression in murine ex-vivo 3D-LTCs 
Despite Nintedanib and Pirfenidone decelerating disease progression, IPF continues to progress. 
Therefore, novel therapeutic options are needed.  Pirfenidone and Nintedanib differentiate in 
their molecular structure and mode of action suggesting that concomitant treatment might show 
additive effects. Recent trials already showed side-effects of co-treatment being tolerable in IPF 
patients (Ogura et al. 2015). Vancheri et al. observed the co- treatment to be superior compared 
to Nintedanib alone regarding the reduced decline of FVC after 12 weeks observation (Vancheri 
et al. 2018a). However, further clinical trials must be awaited. As proof of concept, we co-treated 
fibrotic murine 3D-LTCs with both low concentration of Nintedanib and Pirfenidone and found 
an additive effect in decreasing mesenchymal gene expression ex-vivo. With our findings 




6.2.3 The anti-fibrotic action of Nintedanib and Pirfenidone in human ex-vivo 3D-LTCs 
Human 3D-LTCs represent a unique possibility for ex-vivo preclinical drug testing within an intact 
human microenvironment. Thus, investigating the anti-fibrotic impact of Nintedanib and 
Pirfenidone in human 3D-LTCs, in particular, can be of special interest. For this approach we used 
human 3D-LTCs from lung cancer resections either treated with TGF-β alone or a fibrotic cocktail 
in the presence of Nintedanib or Pirfenidone. Interestingly, both Nintedanib and Pirfenidone did 
not sufficiently downregulate pro-fibrotic marker expression in human 3D-LTCs upon a fibrotic 
stimulus (TGF-β and FC). This might be due the heterogeneity of the utilized human material, for 
instance due to genetic polymorphism and the potential impact of the underlying disease. In this 
regard, further evaluation with more replicates and a detailed characterization of the clinical 
cohort is needed.  
Our results might also reflect the great heterogeneity within the IPF patient collective regarding 
course of disease and drug efficacy that need to be addressed in both daily clinical practice and 
basic science (Ley, Collard and King 2011, Selman et al. 2007). Therefore, the identification of 
distinct subgroups cannot only help to predict drug responsiveness but allow a more personalized 
therapy (Magnini et al. 2017). In this context, ex-vivo preclinical models can possibly help to 
distinguish between the different disease endotypes according to their molecular characteristics 
and may predict in-situ drug efficacy.  For instance, 3D pulmospheres generated from IPF lung 
tissue biopsies have already been utilized as a multicellular model to evaluate the anti-fibrotic 
drug responsiveness in patients ex-vivo. In fact, Surolia et al. were able to show that the 
generated 3D pulmospheres treated with either Nintedanib or Pirfenidone ex-vivo reflected how 
well a patient responded to anti-fibrotic therapy in-situ (Surolia et al. 2017). However, the multi-
step process necessary to form 3D pulmospheres with the ECM being digested can induce 
profound cellular alterations.  In this regard, 3D-LTCs punches directly generated from lung 
biopsies can be a possible alternative approach to predict drug efficacy ex-vivo. However, a 




6.3 Differential effects of Nintedanib and Pirfenidone on epithelial cell phenotype and function 
in pmAT II cell culture and ex-vivo 3D-LTCs 
IPF disease is driven by impaired epithelium secreting a plethora of pro-fibrotic cytokines which 
initiates fibroblast activation and extracellular matrix accumulation and a vicious cycle of 
impaired epithelial-mesenchymal crosstalk starts thereof. Hence, targeting the abnormal 
alveolar epithelium in fibrosis can be a considerable therapeutic option (Königshoff and Bonniaud 
2014). However, the question in which way the epithelium should be targeted can be raised as 
both proliferation of hyperplastic alveolar epithelium and apoptosis/cellular senescence have 
been demonstrated to contribute to fibrosis (Uhal 2003, Königshoff and Bonniaud 2014, 
Lehmann et al. 2017). Subsequent inhibition of alveolar epithelial cell proliferation via a 
deoxycytidine kinase (DCK) inhibitor as well as depletion of senescent alveolar epithelial cells 
showed favorable effects in the treatment of experimental fibrosis (Weng et al. 2014, Lehmann 
et al. 2017). In this context it can be of particular interest, if Nintedanib and Pirfenidone, the two 
approved drugs in the treatment of IPF, affect alveolar epithelial cell function in a favorable way. 
Furthermore, the delineation of the exact mode of action can possibly help to identify novel 
therapeutic targets. Yet, up to date little is known about Nintedanib and Pirfenidone affecting 
not only fibroblast but also epithelial cell function. Kamio et al. reported Surfactant protein D (SP-
D) expression in human alveolar epithelial cells to be induced upon Nintedanib treatment via the 
c-Jun N-terminal kinase-activator protein-1 pathway (Kamio et al. 2015). SP-D has been 
previously linked to mortality predictions in IPF patients and was, therefore, used as biomarker 
for increased lung injury in the disease (Barlo et al. 2009). However, these findings can be a 
matter of debate as they used supraphysiological concentrations of Nintedanib (3-5µM) while 
Nintedanib plasma levels are around 70nM when treating patients with the standard dose 
(150mg twice a day). Therefore any observations using these high concentrations might be 
without clinical relevance (Wollin 2015). In the case of Pirfenidone it can be similarly reasoned 
with any concentration above 100µM being not relevant in the clinical setting. Here we argue as 
we use concentrations slightly exceeding the plasma concentrations of patients that these might 
still recapitulate the concentration found in the lung with the compound accumulating in the 
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tissue. Moreover, the drug availability in 3D-LTCs might differ from the pharmacokinetics within 
as living organism due to altered cell metabolism and drug distribution.  Nevertheless, it cannot 
be excluded that using concentrations exceeding the in-situ plasma levels in patients and the 
direct exposure of cells results in further off target effects.  
 
6.3.1 Nintedanib and Pirfenidone inhibit TGF-β induced EMT in alveolar epithelial cells  
EMT plays a crucial role in early life during lung development and later in the pathogenesis of 
cancer metastasis and chronic lung diseases (Jolly et al. 2018). However, EMT as potential 
myofibroblast source in IPF pathogenesis remains controversial (Fernandez and Eickelberg 
2012b, Wolters, Collard and Jones 2014, Rock et al. 2011). Recent fate mapping studies in mice 
showed alveolar epithelial cells to express mesenchymal marker upon TGF-β or Bleomycin 
treatment (Kim et al. 2006, Tanjore et al. 2009). Willis et al. similarly demonstrated cellular 
subpopulations expressing both mesenchymal and epithelial cell markers in IPF tissue (Willis et 
al. 2005). However, the detection of this hybrid cell phenotype doesn’t necessarily implicate a 
complete epithelial cell into myofibroblast transdifferentiation (Jolly et al. 2018). Nevertheless, 
these cells can promote fibrogenesis by secreting multiple pro-fibrotic factors without directly 
contributing to the myofibroblast population (Lovisa, Zeisberg and Kalluri 2016, Hill et al. 2019). 
Initially, EMT is part of a physiological repair process occurring in response to injury. After injury, 
adjacent epithelial cells and subsequently progenitor cells spread and migrate to reestablish the 
disrupted epithelial layer upon the secretion of a plethora of growth factors and cytokines 
(Crosby and Waters 2010).  In this process these cells partially undergo phenotypic changes 
including EMT. It is characterized by the loss of E-cadherin mediated cell-cell contact and apical-
basal polarity and the simultaneous gain of mesenchymal markers leading to the formation of a 
reversible hybrid epithelial-mesenchymal cell phenotype (Jolly et al. 2015). EMT can be triggered 
by multiple growth factors/cytokines including TGF-β and Wnt-signaling and cellular stress 
responses, such as ER stress and unfolded protein response (UPR) (Jolly et al. 2018, Yu et al. 
2008). However, the perpetuation of EMT-initiating signals causes an aberrant repair process 
resulting in ECM accumulation, ultimately leading to organ fibrosis (Salton, Volpe and 
Confalonieri 2019). Recent studies reported that both Nintedanib and Pirfenidone suppress TGF-
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β induced epithelial to mesenchymal transition (EMT) in cancer cell lines with Nintedanib 
upregulating E-cadherin expression (Fujiwara et al. 2017, Huang et al. 2015, Kurimoto et al. 2017). 
Along with this, we show the inhibition of fibrotic marker, Fn1 and Col1a1, by Nintedanib and 
Pirfenidone in pmAT II cells after TGF-β treatment.  However, E-cadherin was not reconstituted 
on gene expression level (data not shown). Interestingly, we observed E-cadherin and Zo1 
expression to be increased upon Nintedanib treatment in human 3D-LTCs. It highlights again the 
differences of results dependent on the selected read-out and demonstrates the potential impact 
of retained microenvironment and/or particular human epithelial cell properties that might play 
a role in restoring epithelial cell integrity.   
 
6.3.2 Nintedanib and Pirfenidone differentially affect alveolar epithelial cell phenotype 
It is well accepted that alveolar type II (AT II) cells serve as progenitor cells during lung 
homeostasis and injury reconstituting the intact barrier by differentiating to ATI cells (Selman 
and Pardo 2006). In fibrosis the renewal capacity of AT II cells is impaired. Recent studies 
demonstrated that disturbed regeneration of the epithelium led to severe fibrosis and increased 
mortality in the bleomycin mouse model (Liang et al. 2016, Richeldi, Collard and Jones 2017). 
Moreover, the targeted damage of AT II cells subsequently leading to apoptosis resulted in the 
devolvement of fibrosis in mice highlighting the importance of epithelial cells retaining lung 
homeostasis (Sisson et al. 2010). However, not only alveolar epithelial cell apoptosis, but 
induction of p53-depended cellular senescence in AT II cells was demonstrated to lead to lung 
fibrosis (Yao et al. 2019). Therefore both epithelial cell apoptosis and cellular senescence upon 
injury and subsequent hyperplasia contribute to disease perpetuation making it to promising 
therapeutic targets (Königshoff and Bonniaud 2014). In this context a more in depth 
understanding of how Nintedanib and Pirfenidone might affect epithelial cells, may lead to novel 
therapeutic approaches directly targeting alveolar epithelial cells in IPF. Here we show that AT II 
cell marker Surfactant protein C expression was both downregulated in pmAT II cells and 3D-LTCs 
upon injury. This can be either due to increased apoptosis of AT II cells or decreased Surfactant 
protein C expression as AT II cells loose epithelial cell properties undergoing EMT. Interestingly, 
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AT I cell marker T1α expression was upregulated in fibrotic pmAT II possibly indicating an 
attempted repair mechanism by AT II cells differentiating into AT I cells.  Nintedanib, but not 
Pirfenidone treatment subsequently restored proSP-C protein expression and secretion in 
murine and human 3D-LTCs. Observing similar effects in pmAT II monoculture it can be argued 
that the upregulation of pmAT II cell marker is conveyed by a direct impact of Nintedanib on 
epithelial cells and not as a result of cell-cell interactions.  For more mechanistic insights we 
checked for Nkx2.1, a transcription factor pivotal for AT II differentiation and lung morphogenesis 
(Liebler et al. 2016), and found it to be upregulated by Nintedanib suggesting that pro-SPC 
expression is partly mediated via Nkx2.1. Interestingly, both AT I marker T1α and Hopx are 
upregulated upon Nintedanib and Pirfenidone indicating induced increased AT I cell formation. 
This might be indicative for Nintedanib inducing physiological repair mechanisms in the lung with 
AT II differentiating to AT I cells. In fact, Hopx, which is proposed to be marker for the 
regenerative capacity of epithelial cells (Ota et al. 2018), is downregulated in fibrotic pmAT II cells 
after 5 days in culture with epithelial cells losing their ability for renewal and subsequently 
increased upon Nintedanib and Pirfenidone suggesting that the treatment might be beneficial 
for restoring the regenerative potential in epithelial cells. However, neither Nintedanib nor 
Pirfenidone were capable of upregulating Hopx in the human 3D-LTCs upon the fibrotic cocktail. 
Further insights using human alveolar epithelial type II cells could be of benefit in this regard.  
We report here that Nintedanib significantly induced the AT II cell marker Sftpc (SFTPC) 
expression in both pmAT II monoculture and murine and human 3D-LTCs whereas Pirfenidone 
had no such effect. However, whether the AT II cell marker induction represents an increase in 
the total number of functional viable epithelial cells or the already existing epithelial cells express 
more Surfactant Protein C needs to be further evaluated.  
 
6.3.3 Nintedanib and Pirfenidone interfere with an aberrant epithelial-mesenchymal-crosstalk 
by decreasing Wisp1 secretion  
Due to the repetitive injury in fibrosis the epithelial phenotype and function is altered leading to 
apoptosis and hyperplasia with increased proliferate capacity, recapitulation of developmental 
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and pro-fibrotic pathways (Richeldi et al. 2017, Konigshoff et al. 2009). It is well accepted that 
canonical WNT/β-catenin signaling is increased in a variety of cell types in IPF (Baarsma and 
Konigshoff 2017). Königshoff et al. demonstrated the canonical ligand Wnt1 to be largely 
enriched in both hyperplastic AT II cells and bronchial epithelium with β-catenin and Gsk-3β being 
localized to the nucleus (Konigshoff et al. 2008). Moreover, targeting Wisp1, a potent inducer of 
epithelial cell proliferation and EMT in-vitro, with neutralizing antibodies led to the attenuation 
of Bleomycin induced lung fibrosis in-vivo proving genes regulated by WNT signaling to be 
promising therapeutic targets (Konigshoff et al. 2009). In order to investigate if Nintedanib and 
Pirfenidone affect WNT target expression, we analyzed Wisp1 secretion in murine 3D-LTCs and 
found it to be downregulated leading to the assumption that both drugs partly interfere with the 
impaired epithelial-mesenchymal-crosstalk in fibrosis via Wisp1.  As Wisp1 is predominately 
expressed by AT II cells, we continued by treating pmAT II cells with Nintedanib and Pirfenidone 
upon TGF-β stimulation. Notably, we observed Wisp1 being induced by TGF-β in pmAT II cells 
which has been previously described in primary human fibroblasts (Berschneider et al. 2014, Klee 
et al. 2016). We found Wisp1 secretion to be downregulated by Nintedanib and Pirfenidone in 
pmAT II cells suggesting that the effect is directly mediated via AT II cells. However, whether 
Pirfenidone and Nintedanib downregulate Wisp1 secretion via inhibiting TGF-β signaling or by 
directly targeting WNT-signaling remains unclear. Further investigations are needed to unravel 
the exact mode of action. 
 
6.4 Conclusions 
Firstly, we demonstrated that murine 3D-LTCs represent a valuable approach for pre-clinical drug 
testing ex-vivo, thus limiting the number of animals being used for experimentation. We further 
validated the applicability of the Fibrotic Cocktail inducing “early fibrosis like” changes in human 
3D-LTCs for testing the anti-fibrotic action of compounds, using Nintedanib and Pirfenidone as 
an example. The acquired data can possibly be held as reference standard for testing future 
compounds using ex-vivo 3D-LTCs. However, we also pointed out the systems limitations with 
highlighting the need of combining multiple approaches for pre-clinical drug testing. Given the 
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complexity of the system of human 3D-LTCs, the deployment of high throughput analysis in order 
to identify suitable marker for the treatment response will be crucial.  
Secondly, we provide evidence of Nintedanib and Pirfenidone affecting alveolar epithelial cell, 
thus contributing to a better overall understanding of the anti-fibrotic action of both drugs. We 
present evidence of Nintedanib and Pirfenidone differentially affecting alveolar epithelial cell 
function both in pmAT II cell culture and ex-vivo 3D-LTCs.  We demonstrated Nintedanib to 
stabilize phenotypic marker for alveolar type I and II cells and show evidence of Nintedanib 
restoring the regenerative potential of the alveolar epithelium. Furthermore, both Pirfenidone 
and Nintedanib were shown to prevent TGF-β induced EMT in alveolar type II cells. However, to 
what extent Nintedanib and Pirfenidone restore epithelial cell function and if this adds to the 
anti-fibrotic action of these drugs in-situ needs to be further delineated.  
 
6.5 Future perspective 
Nintedanib and Pirfenidone are the only approved drugs in the treatment of IPF patients known 
to decelerate disease progression and reduce mortality (Richeldi et al. 2017). Their clinical 
success can be mainly attributed to their pleiotropic anti-fibrotic effects on multiple cell types in 
the disease. However, IPF continues to progress upon Nintedanib or Pirfenidone treatment and 
novel treatment approaches are needed. In this regard, combined therapy with Nintedanib and 
Pirfenidone was shown to have additive effects. (Vancheri et al. 2018b). Further clinical trials 
must be awaited.  As recent more selective therapeutic strategies failed to show sufficient anti-
fibrotic effects in-situ (Daniels et al. 2004, Aono et al. 2005, Daniels et al. 2010), compounds 
affecting multiple cell types and interfering with various pathways might be the key to clinical 
success. Moreover, considering the heterogeneity within the IPF disease “personalized 
combination therapy” as a novel approach using highly diverse anti-fibrotic agents, such as 
Nintedanib and Pirfenidone, with targeted therapies according to patient’s individual background 
can be advantageous in order to maximize the clinical success (Hambly and Kolb 2016, Martinez 
et al. 2017). In this regard, specifically targeting the alveolar epithelial cell dysfunction can be of 
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particular interest for patients with genetic variants of SFTPC and SFTPA associated with 

















































































Supplemental Figure 1: Dose dependent effect of Nintedanib and Pirfenidone on murine 3D-LTC metabolic activity. Control 
and fibrotic 3D-LTCs were subjected to Nintedanib (0.1µM, 1µM, 10µM) and Pirfenidone (100µM, 500µM, 2.5mM) and 
cultured for 48h. Metabolic activity was assessed by WST-1 assay, one-sample t-tests compared to the theoretical value of 
100. *p < 0.05, **p < 0.01, ***p < 0.001 
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Supplemental Figure 2: Maintenance of control and fibrotic 3D-LTCs in culture. Control and fibrotic 3D-LTCs were generated 
as previously described. (A) 3D-LTCs were cultured for 48h.  Fibrotic marker Acta2 gene expression in fibrotic 3D-LTCs 
compared to PBS control was investigated by qPCR (n=7), paired Student‘s t-test.  (B) 3D-LTCs were cultured up to seven days. 
Fibrotic marker Fn1 and Col1a1 and alveolar type II cell marker Sftpc gene expression in fibrotic 3D-LTCs compared to PBS 
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Supplemental Figure 3:  Nintedanib and Pirfenidone affecting fibrotic gene and protein expression in control 3D-LTCs. (A) 
Murine 3D-LTCs were subjected to Nintedanib or Pirfenidone and cultured for 48h. Fibrotic marker Fn1 and Col1a1 gene 
expression was investigated by qPCR (n=3-6), one-sample t-test compared to the theoretical value of 0. (B) Representative 
immunofluorescence images of Collagen I. (C) IL-6 secretion was measured by ELISA (n=3-4), one-sample t-test compared to 
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Supplemental Figure 4: Effect of Nintedanib and Pirfenidone on fibrotic marker expression in PBS treated 3D-LTCs. (A) 
Murine 3D-LTCs were treated with Nintedanib and Pirfenidone for 48h. Fibrotic marker Fn1 and Col1a1 gene expression was 
investigated by qPCR (n=3-6), one-sample t-tests compared to the theoretical value of 0. (B) Collagen I secretion was 
investigated by Western blot (n=4), paired Student‘s t-test. *p < 0.05, **p < 0.01, ***p < 0.001           
 





























































































































Supplemental Figure 5: Effect of Nintedanib and Pirfenidone on epithelial cell function in control 3D-LTCS. (A, B) Murine 
3D-LTCs were subjected to Nintedanib (A: 1µM; B: 0.1µM, 1µM) and Pirfenidone (A: 500µM; B: 100µM, 500µM) and cultured 
for 48h. (A) Western blot analysis of pro-SPC expression (n=3), paired Student’s t-test. (B) Wisp1 secretion was determined 















































































Supplemental Figure 6: Effect of Nintedanib and Pirfenidone on epithelial cell function in PBS treated 3D-LTCs. (A, B, C) 
Fibrotic murine 3D-LTCs were subjected to Nintedanib (1µM) and Pirfenidone (500µM) for 48h. (A) Western blot analysis of 
pro-SPC expression (n=4-5), paired Student’s t-test. (B) SP-C and WISP1 secretion was determined by ELISA, paired Student’s 
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Supplemental Figure 7: Effect of Nintedanib and Pirfenidone on control pmAT II cells. (A, B) PmAT II cell were cultured with 
Nintedanib (A: 0.1µM, 1µM; B: 1µM) or Pirfenidone (A: 100µM, 500µM; B: 500µM) for 48h.(A) Fibrotic marker Fn1 and Col1a1 
gene expression was investigated by qPCR (n=3-5), one-sample t-tests compared to the theoretical value of 0. (B)  Western 
blot analysis of collagen I expression (n=3), paired Student’s t-test. (C) IL-6 secretion was determined by ELISA (n=3-7), one-
sample t-tests compared to the theoretical value of 1. *p < 0.05, **p < 0.01, ***p < 0.001 







































































Supplemental Figure 8: Effect of Nintedanib and Pirfenidone on pmAT II cells derived from PBS treated mice. Fibrotic 
marker Fn1 and Col1a1 gene expression in control pmAT II cells treated with Nintedanib (1µM) or Pirfenidone (500µM) for 















































































































































































Supplemental Figure 9: Nintedanib and Pirfenidone affecting epithelial cell function in control pmAT II cells. PmAT II cell 
were cultured with Nintedanib) or Pirfenidone for 48h. (A) Epithelial cell marker Sftpc, Nkx2.1, T1α and Hopx gene expression 
was investigated by qPCR (n=3-6), one-sample t-tests compared to the theoretical value of 0. (B) Wisp1 secretion was 
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Supplemental Figure 10: Effect of Nintedanib and Pirfenidone on pmAT II cells derived from PBS treated mice. PmAT II cell 
were cultured with Nintedanib (1µM) or Pirfenidone (500µM) for 48h. (A) Epithelial cell marker Sftpc, Nkx2.1, T1α and Hopx 





























































































































Supplemental Figure 11: Ex-vivo effect of Nintedanib and Pirfenidone on fibrotic gene expression in control human 3D-
LTCs. Human 3D-LTCs were cultured with Nintedanib (1µM) or Pirfenidone (500µM) for 48h. Fibrotic marker Fn1 and Col1a1 
gene expression was investigated by qPCR (N=6), paired Student’s t-test.  




































Supplemental Figure 12: Metabolic activity of human 3D-LTCs cultured with CC/FC and Pirfenidone and Nintedanib. 
Punches were treated with CC/FC and Pirfenidone (5µM) and Nintedanib (1 μM) for 120h. Metabolic activity was assessed by 



















































































































































































Supplemental Figure 13. Ex-vivo effect of Nintedanib and Pirfenidone on epithelial cell function in control human 3D-LTCs. 
(A, B) Human 3D-LTCs were cultured with Nintedanib (1µM) or Pirfenidone (500µM) for 48h. (A) Epithelial cell marker CDH1, 
ZO1, SFTPC, NKX2.1 and T1α gene expression was investigated by qPCR (N=5-6), paired Student’s t-test (B) Pro-SP-C secretion 
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